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The type 2 diabetes mellitus (T2DM) was one of the most significant public health challenges in 
21th century. The T2DM in most instances are characterized by alteration in insulin secretion and insulin 
sensitivity or a combination of both. For the last decade, a lot of attention has been focused on insulin 
resistance as a critical cause on development of T2DM. However, after many years from diagnosis of 
the T2DM, individuals with the disease were largely accompanied by continuous decline in β-cell 
function. Indeed, pancreatic β-cells have vital role in pathogenesis of T2DM and understanding β-cells 
physiology can reliably alleviates the disease. Thus, in the future, cure for T2DM will require genetic 
or pharmacological approaches to be beneficial to β-cells. Here, I focused the phospholipase Cβ (PLCβ) 
for elucidation of molecular aetiology for T2DM and zafirlukast drug for effective interventions to 
combat T2DM epidemic. 
In the first chapter of this dissertation, I reviewed overall regulatory mechanism of insulin 
secretion, especially focused on PLCβs and high-throughput tools for discovering regulator of insulin 
secretion. In the second chapter, I described the PLCβ1-mediated insulin secretion. Phospholipase Cβ 
(PLCβ) exerts biological influences through G protein-coupled receptors (GPCRs). GPCRs are 
involved in regulating glucose-stimulated insulin secretion (GSIS). Previous studies have suggested 
that PLCβs might play an important role in pancreatic β-cells. However, due to a lack of the specific 
inhibitors of PLCβ isozymes and appropriate genetic models, the in vivo function of specific PLCβ 
isozymes in pancreatic β-cells and their physiological relevance in the regulation of insulin secretion 
has not been studied so far. The present study showed that PLCβ1 was crucial for β-cell function by 
generation of each PLCβ conditional knockout mice. Mice lacking PLCβ1 in β-cells exhibited a marked 
defect in GSIS, leading to glucose intolerance. In ex vivo studies, the secreted insulin level and Ca2+ 
response in Plcb1f/f; Pdx1-CreERt2 islets was lower than those in the Plcb1f/f islets under the high 
glucose condition. PLCβ1 led to potentiate insulin secretion via stimulation of particular Gq protein-
coupled receptors. Plcb1f/f; Pdx1-CreERt2 mice fed a high fat diet developed more severe glucose 
intolerance due to a defect in insulin secretion.  
In the last chapter, I reported a novel function of zafirlukast as insulin secretagogue. The 
zafirlukast has been reported to be anti-inflammatory and widely used to alleviate the symptoms of 
asthma. However, its influence on insulin secretion in pancreatic β-cells has not been investigated. 
Herein, we examined the effects of zafirlukast on insulin secretion and the potential underlying 
mechanisms. Among the cysteinyl leukotriene receptor 1 antagonists, zafirlukast, pranlukast, and 
montelukast, only zafirlukast enhanced insulin secretion in a concentration-dependent manner in both 
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low and high glucose conditions and elevated the level of [Ca2+]i, further activating Ca2+/calmodulin-
dependent protein kinase II (CaMKII), protein kinase B (AKT), and extracellular signal-regulated 
kinase (ERK) signaling. These effects were nearly abolished by the L-type Ca2+ channel antagonist 
nifedipine, while treatment with thapsigargin, a sarco/endoplasmic reticulum Ca2+ ATPase inhibitor, did 
not have the same effect, suggesting that zafirlukast primarily induces the entry of extracellular Ca2+ 
rather than intracellular Ca2+ from the endoplasmic reticulum. Zafirlukast treatment resulting in a 
significant drop in glucose levels and increased insulin secretion in C57BL/6J mice.  
The present study identified PLCβ1 and zafirlukast as an important factor that regulates β-cell 
insulin secretion. These findings will contribute to an improved understanding of the β-cell 








Abstract  ········································································································  i 
Contents  ·····································································································  iv 
List of Figures  ······························································································  vi 
List of Tables ································································································ viii 
Abbreviations  ·······························································································  ix 
 
Chapter I. Background  ···················································································  1 
1.1. Diabetes mellitus – Type II diabetes  ·································································  1 
1.2. Mechanism of insulin secretion  ······································································  1 
1.3. PLCβ-mediated regulation of GSIS  ··································································  3 
1.4. Overview of GqPCRs which potentiates GSIS through PLCβ signaling  ························  5 
1.5. High-throughput luminescent reporter of insulin secretion  ·······································  8 
1.6 Reference  ······························································································· 17 
 
Chapter II. Phospholipase Cβ1 potentiates glucose-stimulated insulin secretion  ············· 25 
2.1. Introduction  ···························································································· 25 
2.2. Materials and methods  ················································································ 26 
2.3. Results  ·································································································· 31 
2.4. Conclusion and Discussion  ·········································································· 35 
2.5. Reference ······························································································· 54 
 
Chapter III. Zafirlukast promotes insulin secretion by increasing calcium influx through L-type 
calcium channels  ·························································································· 59 
3.1. Introduction  ···························································································· 59 
3.2. Materials and methods  ················································································ 60 
3.3. Results  ·································································································· 62 
3.4. Conclusion and Discussion  ·········································································· 65 




Chapter IV. Acknowledgements  ········································································ 80 
vi 
 
List of Figures 
 
Figure 1.1. Vascularization and innervation of Langerhans islets 
Figure 1.2. Structure of mammalian PLC isotypes and detailed action of PLCβs 
Figure 1.3. PLCβ as key molecule of GPCR signaling 
Figure 1.4. Overview of phospholipase Cβ-mediated insulin secretion pathways 
Figure 1.5. Schematic diagram of a proinsulin-luciferase fusion protein and validation of luciferase 
activity as a proxy for secreted insulin 
Figure 2.1. Expression profile of PLCβ isozymes in pancreatic β-cells 
Figure 2.2. Inducible ablation of PLCβ isozymes in adult pancreatic β-cells 
Figure 2.3. Impaired glucose tolerance in Plcb1f/f; Pdx1-CreERt2 mice 
Figure 2.4. Defect in GSIS in Plcb1f/f; Pdx1-CreERt2 mice 
Figure 2.5. Normal insulin production and islet morphology 
Figure 2.6. Decreased selective GqPCR-induced insulin release in Plcb1f/f; Pdx1-CreERt2 islets 
Figure 2.7. Impaired insulin secretion in Plcb1f/f; Pdx1-CreERt2 mice fed a HFD 
Figure 2.8. Similar body weight and fasting and re-feeding glucose levels between control and PLCβ 
cKO mice following tamoxifen treatment 
Figure 2.9. Normal insulin sensitivity in Plcb1f/f; Pdx1-CreERt2 mice fed a normal chow diet and HFD 
Figure 2.10. PLCβ1 protein expression in α-cell and δ-cells in pancreatic islets from control and Plcb1f/f; 
Pdx1-CreERt2 islets 
Figure 2.11. Reduced PLCβ1 expression in human β-cells from type 2 diabetes patients compared to 
normal subjects 
Figure 2.12. Reduced PLCβ1 expression in hypothalamus results in no alteration in food intake 
Figure 2.13. No change in β-cell proliferation and β-cell turnover in Plcb1f/f; Pdx1-CreERt2 islets 
Figure 2.14. PLCβ isozyme expression in each PLCβ isozyme conditional knockout islets  
Figure 2.15. Reconstitution of PLCβ1 expression to rescue cells from abnormal insulin secretion  
Figure 3.1. Zafirlukast-dependent potentiation of insulin secretion in MIN6 cells. 
Figure 3.2. Distinct effect of zafirlukast on insulin secretion among cysteinyl leukotriene receptor 1 
(CysLTR1) antagonists. 
Figure 3.3. Zafirlukast-induced increase in intracellular calcium ([Ca2+]i) in MIN6 cells.  
Figure 3.4. Increase in insulin secretion and [Ca2+]i following stimulation with zafirlukast in primary 
pancreatic islets. 
Figure 3.5. Zafirlukast-induced phosphorylation of CaMKII, AKT, and ERK. 
vii 
 
Figure 3.6. Effect of zafirlukast on insulin secretion elicited by extracellular Ca2+ influx through L-type 
voltage dependent calcium channels (L-VDCCs). 
Figure 3.7. Glucose-lowering effect of zafirlukast as a result of increased insulin secretion in vivo. 
Figure 3.8. Pranlukast- and montelukast-induced phosphorylation of CaMKII, AKT, and ERK. 
Figure 3.9. Effect of zafirlukast on [Ca2+]i in Ca2+-free Kreb’s buffer (KRB) medium. 
viii 
 
List of Tables 
 
Table 1.1. GPCRs highly relevant Gq/PLCβ signaling for stimulating insulin secretion 







AC Adenylyl cyclase 
AKT Protein kinase B 
AMS α-methyl serotonin maleate salt 
AT1 Angiotensin II receptor 1 
AVP Vasopressin 
CaMKII Ca2+/calmodulin-dependent protein kinase II 
cAMP Cyclic adenosine 3 ,́5 -́ monophosphate 
CCK Cholecystokinin-8 
CNS Central nervous system 
CysLTR1 Cysteinyl leukotriene receptor 1 
DAG Diacylglycerol 
DHP Dihydropyridine 
DM Diabetes mellitus 
EC50 Half maximal effective concentration 
ELISA Enzyme-linked immunosorbent assay 
Emax Maximum effect concentration 
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinase 
FFA1 Free fatty acid receptor 1 
FRET Fluorescence resonance energy transfer 
GFP Green fluorescent protein 
GLUT2 Glucose transporter 2 
GPCR G protein-coupled receptor 
GSIS Glucose-stimulated insulin secretion 
HFD High-fat diet 
HTR2B Serotonin receptor 2B 
IHC Immunohistochemistry 
IL-6R Interleukin (IL)-6 receptor 
IP3 Inositol triphosphate 
IP3R inositol trisphosphate receptors 
IP4 Inositol 1,3,4,5-tetrakisphosphate 
x 
 
KATP channels ATP-sensitive K
+ channels 
KP Kisspeptin-10 
L-VDCC L-type voltage dependent Ca2+ channel 
MCP-1 Monocyte chemotactic protein 1 
NSAID Non-steroidal anti-inflammatory drug 
OA Oleic acid 
OLFR15 Olfactory receptor 
OXO-M Oxotremorine-M 
Pdx1 Pancreas/duodenum homeobox protein 1 
PDZ Postsynaptic density protein 95, disc large, zona occludens-1 
PH Pleckstrin homology 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PKA Protein kinase A 
PKC Protein kinase C 
PLCβ Phospholipase Cβ 
PPAR-γ Proliferator-activated receptor-γ 
SOC Store-operated channel 
T1DM Type 1 diabetes 
T2DM Type 2 diabetes 
TRPC Transient receptor potential channel 
5-HT Serotonin 






1.1. Diabetes mellitus – Type II diabetes 
 
The Diabetes mellitus (DM) is chronic condition in which individuals gradually lose capacity to 
regulate blood sugar (glucose), referred to as hyperglycemia. It causes high risk for micro- and 
macrovascular complications such as retinopathy, nephropathy, and cardiovascular comorbidities [1]. 
In a recent decades, this disease have been globally epidemic that the International Diabetes Federation 
reported 425 million adults have diabetes and expected to rise to 629 million by 2045 [2]. In 1936, the 
distinct definition between type 1 diabetes (T1DM) and type 2 diabetes (T2DM) was clearly described 
[3]. T1DM is primarily developed by autoimmune response against pancreatic β-cells, leading to 
absolute insulin deficiency. Individuals with T1DM are totally dependent on exogenous insulin to 
control blood glucose levels. T2DM, far more common type of diabetes, which accounts for more than 
90% of all diabetes cases, is due to insulin resistance and/or abnormal insulin secretion. T2DM is 
heterogeneous disease resulting from genetic and environmental risk factors. Patients with T2DM 
require change in life style or hypoglycemic agents [4]. Epidemiological studies show that β-cells 
function start to decline after several years from clinical diagnosis and β-cells lose capacity to 
hypersecrete insulin to overcome insulin resistance [5]. The β-cell dysfunction includes reduction in 
insulin secretion to glucose [6] and non-glucose secretagogues [7, 8], change in pulsatile and oscillatory 
trends of insulin secretion [9, 10], alteration in proinsulin to insulin conversion [11, 12]. With systemic 
understanding for insulin resistance of glucose recipient tissues such as muscle, adipose tissue and liver, 
comprehensive studies about β-cell function in progression of T2DM are essential to true cure for 
T2DM. 
  
1.2. Mechanism of insulin secretion 
 
The main pathophysiology of T2DM is the inability of pancreatic β-cells to properly secrete 
enough insulin in response to various stimuli, including high glucose [13, 14]. In addition to glucose, 
hormonal factors, such as vasopressin, glucagon-like peptide 1, cholecystokinin, and neuronal factors, 
such as acetylcholine and serotonin, plus non-glucose nutrients, such as free fatty acids (FFAs), have 
been reported to participate in potentiating glucose-stimulated insulin secretion (GSIS) [15]. These 
mediators exert their biological effects through G-protein coupled receptors (GPCRs), which have been 
reported to stimulate insulin secretion by increasing insulin exocytosis [16, 17]. This stimulation 
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includes an increase in cytosolic Ca2+ levels and the number of readily releasable granules as well as 
the activation of exocytotic machinery. The phospholipase Cβ (PLCβ) that preferentially couples to the 
Gαq protein of GPCRs has been thought to play an important role in fine-tuning the regulation of insulin 
secretion [18]. Using potent inhibitors and small interfering RNAs, several studies have described 
PLCβs as important regulators in the pathway for insulin release. This review provides a comprehensive 
understanding of the potential regulatory modes of PLCβs in regulating insulin secretion in pancreatic 
β-cells. 
In pancreatic β-cells, glucose is the primary regulator of insulin secretion. Glucose is transported 
into β-cells via glucose transporter 2 (GLUT2) and metabolized, which leads to a rise in the ATP/ADP 
ratio. The relative increase in ATP levels causes closure of ATP-sensitive K+ channels (KATP). Recently, 
it has been reported that exposure of high glucose induced KATP channel endocytosis and reduced 
surface KATP channels, which contributed to increased glucose responses rather than to ATP-dependent 
gating of KATP channels [19]. Blocking the efflux of K+ results in the depolarization of membrane 
potentials and the opening of L-type voltage-dependent Ca2+ channels (L-VDCC), inducing an influx 
of extracellular Ca2+. The elevated intracellular Ca2+ levels ([Ca2+]i) are involved in the activation of 
Ca2+-related signaling molecules and such components of exocytotic machinery as Ca2+/calmodulin-
dependent protein kinase II [20, 21] and SNARE proteins [22]. This process is known as GSIS. 
In addition to triggering insulin secretion by glucose, GSIS can be augmented by non-glucose 
metabolites, neuronal and hormonal ligands from insulin vesicles, nerve endings, and blood capillaries 
surrounding pancreatic β-cells in an autocrine and paracrine manner in complex Langerhans islets 
(Figure 1.1). These mediators primarily act on surface GPCRs, which activate intracellular signaling. 
The types of GPCRs and their natural ligands that affect the potentiation of insulin secretion have been 
identified (Table 1.1). However, as there may be other GPCRs highly expressed in mouse islets, further 
studies are required to completely understand their putative effects on insulin secretion. The activated 
GPCRs induce dissociation of heterotrimeric G proteins, which propagate intracellular signaling. The 
Gαs and Gαi proteins couple to adenylyl cyclase (AC), and activation of Gαs proteins stimulates AC and 
insulin secretion, but activation of Gαi proteins inhibits this process. The AC catalyzes ATP to 3',5'-
cyclic AMP (cAMP), which results in subsequent activation of protein kinase A (PKA). The PKA 
induces increased insulin secretion by directly phosphorylating exocytotic proteins, such as snapin and 
synaptotagmin [23, 24], increasing the total number of insulin granules available for release [25], 
inactivating KATP channels (phosphorylation site S1448), and activating Cav1.2 channels [26]. The Gαq 
proteins promote lipid-derived signaling through PLCβs, which hydrolyze membrane-bound 
phosphatidylinositides and induce increased [Ca2+]i mobilization. Also, pancreatic β-cells contains a 
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range of nuclear receptors including peroxisome proliferator-activated receptor-γ (PPAR-γ) [27], liver 
X receptor [28] and androgen receptor [29] activated by corresponding ligands such as fatty acids, 
prostaglandins, oxysterols and androgen, respectively. However, phospholipid such as 
phosphoinositides can regulate activity of nuclear receptors [30]. Through PLCβ-mediated generation 
of second messenger phospholipids, GPCRs can mediate activation of nuclear receptors which induce 
gene expression as transcription factor or regulate metabolic function [31, 32], glucose or lipid 
metabolism [28], for proper insulin secretion. Additional details of GqPCRs-PLCβ signaling are 
described below. 
 
1.3. The PLCβ-mediated regulation of GSIS 
 
Distinct structures and expression patterns of PLCβs in pancreatic β-cells 
 
To date, 13 mammalian PLC isozymes have been characterized and classified into six different 
subtypes: PLCβ1-4, PLCγ1,2, PLCδ1,3,4, PLCε, PLCζ, and PLCη1,2 [33]. All isozymes share a highly 
conserved domain. The core domain includes a pleckstrin homology (PH) site, four tandem EF hands, 
a X–Y linker, and a C2 domain [34]. Using the PH domain, PLC anchors phosphatidylinositol 4,5-
bisphosphate (PIP2) and βγ-subunits of G proteins. The EF hand is a known Ca2+-binding region, which 
promotes Gαq-mediated GTP hydrolysis. The X–Y linker contains the catalytic activity. The C2 domain 
regulates PLC activity involving Ca2+-dependent membrane targeting. Additionally, there are other 
unique domains specific to each subtype. Notably, PLCβs contain a postsynaptic density protein 95, 
disc large, zona occludens-1 (PDZ)-binding motif at the C-terminus which interacts with different PDZ 
proteins (Figure 1.2) [35]. Approximately half of GqPCRs also have a PDZ-binding motif at the long 
C-terminal region. Each PLCβ isozyme has different PDZ-binding motifs, enabling each PLCβ to 
interact with specific GqPCRs via particular PDZ proteins [36, 37]. 
The expression patterns and regulation of PLCβs, PLCβ1-4, are somewhat different. PLCβ1 and 
PLCβ4 are enriched in neural tissue, PLCβ2 is limited to hematopoietic cells, and PLCβ3 is more widely 
expressed [38]. In pancreatic β-cells, the expression of PLCβ isozymes has been shown to differ 
according to species, specimen type, and detection method. In rat insulinoma cell lines, such as INS-1 
and betaG 40/110 cells, immunoblotting has shown that PLCβ1, PLCβ2, and PLCβ3 are detectable, but 
the expression levels of these isozymes are slightly reduced in rat islets [39]. The PLCβ1 is especially 
localized in the nucleus as well as the cytoplasm in the mouse insulinoma cell line, MIN6 [40]. 
Regarding rat primary tissue, all PLCβ isozymes have been detected in the islets of Langerhans by 
western blot analyses. Using immunohistochemistry (IHC) of the rat pancreas, PLCβ1 and PLCβ4 have 
4 
 
been found in endocrine tissues. PLCβ2 and PLCβ3 are mainly expressed in the periphery of the islets 
[41]. The use of monoclonal antibodies revealed high levels of PLCβ4 and moderate levels of PLCβ3 
in the pancreatic islets in the IHC of the mouse pancreas. PLCβ1 was mainly found in exocrine tissue 
[42]. However, there is other evidence that both rat and mouse islets express PLCβ1. [43]. Recently, we 
found that PLCβ1, PLCβ3, and PLCβ4 were expressed in the MIN6 cell line and mouse primary islets 
(unpublished data). As the physiological function of each PLCβ isozyme in pancreatic β-cells remains 
largely unknown, it is important to clearly define the regulatory mode of each PLCβ during insulin 
secretion. 
 
Activation of PLCβs by glucose in pancreatic β-cells 
 
Glucose is the most potent component that regulates β-cell functions. In addition to metabolic 
functions, glucose can modulate expression of several genes such as PLCβs. As a result of liquid 
chromatography-mass spectrometry/mass spectrometry-based proteomics of human islets after 24 h of 
high glucose exposure, PLCβ4 was characterized as a differentially abundant protein, with PLCβ4 
downregulated under conditions of high glucose levels [44]. The exposure to high glucose levels for 
several days induced expression of PLCβ1 and endoplasmic reticulum (ER) stress markers, such as 
GRP78, sXBP1, ATF4, and Grp78. Losartan, a selective angiotensin II type 1 receptor blocker, inhibits 
the PLCβ-IP3-Ca2+ pathway and prevents glucose-induced expression of PLCβ1 and ER stress markers, 
leading to alleviated glucose toxicity conditions [45]. Several proteins, including PLCβs, have been 
found to be altered during conditions of high glucose levels, but further studies are required to determine 
how glucose is involved in the regulation of PLCβ expression. 
Insulin secretion is followed by the rapid breakdown of polyphosphoinositides hydrolyzed by 
PLC, and the glucose transported into β-cells is coupled to phosphoinositide-specific phospholipase C 
(PI-PLC) activity [46]. The use of [3H]inositol-labeled phospholipids in islets and high-performance 
anion exchange chromatography revealed that high glucose levels (20 mM) induced early increases in 
inositol 1,4,5-triphosphate (IP3) and inositol 1,3,4,5-tetrakisphosphate (IP4) resulting from the 
breakdown of PIP2 [47]. Additionally, PLCβ1-mediated PIP2 hydrolysis might be critical for insulin 
secretion. Mouse islets respond less to glucose stimulation when compared with rat islets in the second 
phase of potentiation during insulin secretion, showing insufficient increments in PI hydrolysis. This is 
because of the underexpression of PLCβ1 in mouse islets compared to rat islets [43]. 
However, the effect of PI-PLC on insulin secretion is not related to glucose metabolism because 
treatment with glycolytic intermediates, such as glucose 6-phosphate did not alter PLC activity. This 
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might be due to an increase of [Ca2+]i in the submicromolar range. The glucose-induced [Ca2+]i levels 
lead to activation of PLC in pancreatic β-cells [48, 49]. However, little is known about how glucose-
induced oscillations of [Ca2+]i might be related to periodic activations of PLCβs. 
 
PLCβ-mediated downstream pathway for amplifying GSIS 
 
Recently, several reports have described the stimulatory function of newly discovered GqPCRs 
involved in the regulation of insulin secretion (Table 1.1). The activated GqPCR generates Gαq and, in 
turn, activates membrane-associated PLCβs. The PLCβs hydrolyze PIP2 into inositol triphosphate (IP3) 
and diacylglycerol (DAG), which serve as important second messengers in signal transduction [50]. IP3 
is targeted to inositol trisphosphate receptors (IP3Rs) on the ER, inducing Ca2+ mobilization from the 
ER and rapid elevation of cytosolic Ca2+ levels [51] (Figure 1.3). The generation of DAG results in 
subsequent activation of protein kinase C (PKC), increasing insulin granules in the readily-releasable 
pool [52] and activating transient receptor potential (TRP) channels, such as TRPM4/5 [53] and TRPC3 
[54]. The DAG itself may be engaged in insulin secretion. DAG binds to the H567 site of Munc13-1, 
which is a DAG receptor, leading to insulin vesicle priming in pancreatic β-cells [55]. Locally reduced 
PIP2 and increased DAG directly activate TRPC3 [56]. The release of the Gβγ complex also plays a 
role in insulin secretion. When the βγ subunit-binding domains, such as the Gα subunit of the retinal G-
protein transducing or the PH domain of G-protein-coupled receptor kinase 2, were expressed, the Gβγ-
mediated signaling was masked, and insulin secretion was inhibited [57]. Also, the Gβγ-dependent 
pathway is involved in the kisspeptin-10-dependent increase in insulin secretion [58]. However, the role 
of the Gβγ subunit in regulation of insulin secretion is still not definitively known because it serves as 
a negative regulator of voltage-gated calcium channels in neuronal and non-neuronal cells [59]. Besides 
the IP3-mediated release of Ca2+ from internal stores, PLCβ can facilitate a further increase in [Ca2+]i 
by activation of store-operated channels (SOC) [60]. The PLCβ-IP3-induced depletion of Ca2+ in the 
ER enables STIM proteins to oligomerize and translocate to the plasma membrane, where they organize 
SOC with ORAI proteins and trigger store-operated Ca2+ entry. In addition to the GPCR-regulatory 
mode, the PLCβ1 in the nucleus participates in modulating transcription of PPAR-γ, which is critical 
for maintaining β-cell function [40] (Figure 1.4). 
 
1.4. Overview of GqPCRs which potentiates GSIS through PLCβ signaling. 
 




The parasympathetic nervous system contributes to promoting GSIS by releasing acetylcholine, 
a major parasympathetic neurotransmitter, in pancreatic islets. The acetylcholine from nerve endings 
exerts its effects through muscarinic type 1 and 3 (M1 and M3) receptors on pancreatic β-cells [61-63]. 
The activation of muscarinic receptors and insulin secretion is directly related to PLCβ activity. 
Carbachol and oxotremorin M increase PLCβ-induced IP3 production and transient [Ca2+]i and insulin 
secretion, and their effects are abolished by aminosteroid U-73122, a PLC inhibitor [64]. Muscarinic 
receptor stimulation leads to rapid and sustained PLCβ activity, and the periodic activation of PLC is 
tightly regulated by dynamic [Ca2+]i oscillations, whereas sustained PLCβ activity is enhanced by 
increased cytosolic Ca2+ levels from intracellular stores and SOC channels [65]. Cholinergic regulation 
is also involved in insulin-containing granule movement toward proximal regions of the plasma 
membrane. IP3-mediated Ca2+ mobilization by PLCβs during cholinergic activation causes 
Ca2+/calmodulin-dependent phosphorylation of myosin light chains. The phosphorylated myosin 
facilitates recruitment of insulin vesicles to the readily releasable pool [66]. Chronic exposure to high 
glucose or carbachol levels causes β-cell desensitization, reducing the activation of insulin secretion 
and the PLC response following high glucose stimulation [67]. 
 
FFA receptor 1 (FFA1) 
 
Free fatty acid receptor 1 (FFA1) is preferentially expressed in pancreatic β-cells and participates 
in amplifying GSIS [68]. FFA1 can be activated by FFAs including saturated, mono- and 
polyunsaturated medium-to-long-chain fatty acids [69]. PLCβ signaling has an essential role in FFA-
induced insulin secretion [70]. Additionally, treatment with an inhibitor for Gαq, YM-254890, and 
inhibitor for PLC, U73122 and neomycin, results in reduced insulin secretion and FFA1-mediated Ca2+ 
efflux from the ER [71, 72]. The increase in [Ca2+]i induced by stimulation of FFA1 is attenuated by 
nitrendipine, a LTCC blocker, which indicates that not only Gαq-PLCβ-mediated intracellular Ca2+ 
efflux from the ER but also extracellular Ca2+ influx via L-VDCC is also involved in FFA1-induced 
insulin secretion [73]. DAG also exerts synergistic effects on insulin secretion as an activator of L-
VDCC following activation of FFA1 [74]. Additionally, nonselective cation ion channels, such as 
TRPC3 channels, also contribute to the FFA1–PLCβ pathway to augment insulin secretion, showing 
that inhibition of PLC and PKC activities results in reduced NSCC current and decreased GSIS induced 
by FFA1 stimulation [54]. FFA1 also activates the extracellular signal-regulated kinases 1/2 (ERK1/2) 
pathway, which is a downstream pathway of Gαq-PLCβ [75]. However, whether activation of the 




Serotonin receptor (HTR2B) 
 
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter, and its action on the 
central nervous system (CNS) in the regulation of mood and behavior is well-known. However, 5-HT 
is also found outside the CNS, such as in the enterochromaffin cells of the gut and in the platelet and 
pancreatic β-cells [77, 78]. The pancreatic β-cells are able to synthesize 5-HT from 5-
hydroxytryptophan via tryptophan hydroxylase 1 (TPH1), and the expression of TPH1 and the synthesis 
of 5-HT are dramatically increased under conditions in which the ability to secrete insulin has been 
enhanced, such as during pregnancy and the insulin-resistant state [79-81]. The 5-HT is stored in insulin 
vehicles and co-secreted with insulin. These act on surface receptors, primarily Htr2b and Htr3a, in an 
autocrine and paracrine manner [82], leading to potentiating GSIS [83, 84]. The Htr3a is a ligand-gated 
ion channel, and the Htr2b receptor is coupled to the Gαq protein, which activates the PLCβ–IP3 pathway 
to promote an increase in [Ca2+]i. Treatment of cells with 5-HT plus α-methyl serotonin maleate salt 
(AMS) and BW723C86, a Htr2b agonist, results in increased [Ca2+]i [85]. Also, the effects of AMS on 
GSIS disappears upon exposure to the IP3 receptor inhibitor, Xestospongin C [83]. Use of a rapid and 
sensitive method for determining PLC activity revealed that 5-HT induced a robust and rapid depletion 
in [3H]phosphatidylinositol, a prelabeled substrate of PLC, and increased levels of [3H]inositol 
phosphate [86]. Together, these findings suggest that 5-HT receptors, which are GqPCRs, are 
functionally coupled to PLCβ-mediated signaling. 
 
Angiotensin II receptor 1 (AT1) 
 
Angiotensin II (Ang II) induces exocytosis of insulin vesicles through Ang II receptors. The 
angiotensin system has been classically linked to the regulation of blood pressure and fluid balance. 
However, there is an angiotensin-generating system in the pancreas [87], and Ang II receptor 1 (AT1) 
is also expressed in pancreatic β-cells [88]. Ang II induces an increase in [Ca2+]i by promoting both the 
influx of extracellular Ca2+ through L-VDCC and the PLCβ-IP3-mediated efflux of Ca2+ from the ER 
[89]. PLCβ signaling has been shown to be involved in the Ang II-mediated regulation of GSIS. Future 
studies should therefore characterize the role of PLCβ signaling in the Ang II pathway that potentiates 
GSIS. 
 
Interleukin (IL)-6 receptor (IL-6R) 
 
The proinflammatory cytokine, IL-6, affects nonimmune events, such as the induction of glucose 
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metabolism [90]. IL-6R has been localized to pancreatic β-cells, and circulating hepatic IL-6 potentiates 
insulin secretion [91]. Various inhibitors, such as U-73122 and neomycin for PLC and xestospondin C 
for the IP3 receptor, have been used to show that IL-6 enhances GSIS in PLCβ-IP3-dependent pathways. 
Among the isozymes of PLC, PLCβ1 knockdown in MIN6 cells abolishes the stimulatory effect of IL-
6 on GSIS, implying that PLCβ1 plays an important role in the IL-6-induced enhancement of GSIS [92]. 
 
Olfactory receptor (OLFR15) 
 
Olfactory receptors have important functions in olfactory chemo-sensation, by detecting different 
odorants [93]. OLFR15 and OLFR21 are expressed in pancreatic β-cells (OLFR15>>OLFR21) [94]. 
As a ligand for OLFR15, octanoic acid (OA) mediates GSIS potentiation [94]. In the presence of an 
inhibitor for PLC and IP3, neomycin and Xestospongin C, OA-enhanced GSIS is attenuated. 
Additionally, among primary PLCs (PLCβ and PLCγ), inhibition of PLCβ1 results in attenuated 
enhancement of GSIS in response to OA [95], suggesting that the Gq–PLCβ1–IP3 pathway is involved 
in OLFR15-dependent increases in GSIS. 
 
1.5. High-throughput luminescent reporter of insulin secretion 
 
Up to date, measuring secreted insulin level have relied on the enzyme-linked immunosorbent 
assay (ELISA). The ELISA have been most widely used detection platform for assays of β-cell function. 
However, it was required multiple-liquid transferring steps, limited detection range, and high cost (> 
$2~3 per sample), making it challenging for application of high-throughput screening. Degorce et al. 
[96] and Bielefeld-Sevigny et al. [97] pioneered notably in high-throughput screening applications 
based on fluorescence resonance energy transfer (FRET). No-wash assays such as time-resolved FRET 
(TR-FRET) and AlphaLISA immunoassay platform exhibit improved sensitivity, extensive dynamic 
range alternative to conventional ELISA. While these assays suited for larger format experiments, they 
still are comparably expensive ($0.6~1.7 per sample) and require advanced hardware compatible with 
these assays. 
There have been many attempts to replace the ELISA using surrogate marker such as green 
fluorescent protein (GFP) or luciferase cloned to the end of the insulin propeptide and co-secreted with 
insulin [98, 99]. While intensity of GFP and luciferase was increased in high glucose condition, they 
were highly correlated with insulin level measured by ELISA. Moreover, constructs including surrogate 
markers have possibility to be misfolded in cells, leading to detrimental effects on cell function [100]. 
Indeed, more than 95% of a proinsulin-firefly luciferase fusion construct was retained in the ER and 
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cells expressing proinsulin-Gaussia luciferase fusion protein had less potency to secrete insulin upon 
high glucose stimulation than control cells. 
Burns SM et al. developed a luminescent insulin secretion assay for tracking insulin secretion in 
rapid and inexpensive way, enabling high-throughput screening application (Figure 1.5). Gaussia 
luciferase was inserted in replace of C-peptide portion of proinsulin, flanked by cleave sites for 
proinsulin convertase (Figure 1.5A). Luciferase was co-localized with insulin in cells stably expressing 
the construct, insulin secretion was highly correlated with luciferase, and fusion protein was not retained 
in the ER. We created stable cell lines expressing reporter construct using lentivirus. Upon stimulation 
with high glucose and oxo-m, muscarinic receptor agonist, cells potentiated insulin secretion and effects 
were disappeared with treatment of diazoxide, ATP sensitive-K+ channel activator. The assay requires 
$0.05 per sample and > 40-fold less time than the conventional ELISA. Also, they exhibit remarkable 
sensitivity and wide dynamic detection range. Using this assay, we screened FDA-approved drug to 
discover a putative candidate which augments insulin secretion. Among, zafirlukast, asthma drug as 
cysteinyl leukotriene receptor 1 antagonist, was selected as novel factor which have not reported as 






Figure 1.1. Vascularization and innervation of Langerhans islets 
The endocrine pancreas is highly entangled by vascularization and innervation, which are critical 
for communication between cells and tissues. The pancreatic islets are comprised of α-cells, β-cells, 
and δ-cells. The autocrine factors are released from insulin-containing vesicles in β-cells, and the 
paracrine mediators are secreted from non-β-cells, blood capillaries, and nerve endings. They exert 
their biological effects mainly by acting on G-protein coupled receptors (GPCRs). In pancreatic β-
cells, phospholipase Cβ (PLCβ) and adenylyl cyclase (AC) generate important second messengers 
to enhance glucose-stimulated insulin secretion (GSIS). The more detailed pathway and 
abbreviations are listed in the Figure 2 legend. This image was revised from figure in mini-review, 




Figure 1.2. Structure of mammalian PLC isotypes and detailed action of PLCβs 
(A) The thirteen kinds of mammalian phospholipase C (PLC) isotypes are classified into six 
isotypes ((β, γ, δ, ε, ζ, η) according to their structure. The PLC isotypes hare a highly conserved 
domain. The PH domain enables PLC to anchors plasma membrane, C2 domain could regulate 
PLC activity, XY domain has catalytic activity and EF hand is Ca2+-binding region which triggers 
GTP hydrolysis of Gαq. The PLCβ isozymes contain different PDZ binding motif which binds to 
particular PDZ scaffolding proteins. (B) The PLCβs selectively catalyzes the hydrolysis of 
phospholipids such as phosphatidylinositol 4,5-bisphosphate (PIP2) on glycerol portion of the 
phosphodiester bond. It results in release of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 









Figure 1.3. PLCβ as key molecule of GPCR signaling 
The PLCβ is one of the enzymes of the six subtypes (β, γ, δ, ε, ζ, and η) that plays a crucial role in 
GPCR-mediated signaling. PLCβ hydrolyzes membrane-bound PIP2 into IP3 and DAG, which are 
important second messengers in the downstream signal pathway, regulating Ca2+ mobilization and 
Protein kinase C (PKC) activation, respectively. The family of PLCβ consists of four isozymes, 
PLCβ1 to PLCβ4, sharing their primary structure. However, each isozyme differs in temporal and 
spatial expression, intracellular distribution, biological and regulatory properties. The PLCβ 
isozymes contain different PDZ binding motifs that recognize specific PDZ scaffolding proteins. 
Various PDZ proteins enable PLCβ to be coupled to specific GPCR signaling pathway. The GPCR-
PLCβ signaling is involved in amplifying GSIS through mainly IP3-Ca2+ pathway and DAG-PKC 
pathway. PLC, phospholipase C; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3, inositol 1,4,5-





Figure 1.4. Overview of phospholipase Cβ-mediated insulin secretion pathways 
As the main regulator of insulin secretion, glucose is transported into the β-cells through GLUT2 
and metabolized, increasing the ATP/ADP ratio. This results in closure of KATP channels and 
endocytosis of KATP channels, inducing membrane depolarization and activation of L-VDCC. The 
extracellular influx of Ca2+ through L-VDCC induces a rise in intracellular Ca2+ ([Ca2+]i), triggering 
insulin secretion. This process is called glucose-stimulated insulin secretion (GSIS). There are 
amplifying pathways for potentiating GSIS. GPCR signaling is mainly involved in the 
augmentation of GSIS by different ligands. Each PLCβ and AC is coupled to Gαq and Gαs proteins 
of GPCRs, respectively. PLCβ hydrolyzes membrane-bound PIP2 into IP3 and DAG, and AC 
generates cAMP, which activates PKA. The IP3 binds to IP3R on the ER and induces Ca2+ efflux 
from internal stores. Ca2+ depletion in the ER activates SOC channels on plasma membranes (PMs), 
inducing the influx of extracellular Ca2+. The increased DAG and activated PKC lead to activation 
of TRP channels. The PKC and PKA directly activate components of exocytotic machinery, 
increasing in RRPs adjacent to the PM. The nuclear PLCβ1 facilitates induction of PPAR-γ 






GLUT2, glucose transporter 2; KATP, ATP-sensitive potassium channel; L-VDCC, L-type voltage-
dependent Ca2+ channel; GPCR, G protein-coupled receptor; TRP, transient receptor potential 
channel; SOC, store-operated channels; RRP, readily-released pool; PLCβ, phospholipase Cβ; AC, 
adenylyl cyclase; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3, inositol 1,4,5-trisphosphate; 
DAG, diacylglycerol; PKC, protein kinase C; ER, endoplasmic reticulum; IP3R, IP3 receptor; ATP, 
adenosine triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; PPAR-γ, 




Receptor name (alias) Natural ligand G protein References 
Muscarinic acetylcholine 
M3 receptor (M3) 
Acetylcholine Gq, (Gs) 





Cholecystokinin-8 Gq, (Gs) 
Br J Pharmacol. (2015) 
172:5050-67 
Free fatty acid receptor 1 
(GPR40, FFA1) 
Mid- and long 
FFAs 
Gq Sci Rep. (2016) 6:25912 
KiSS1-derived peptide 
receptor (GPR54) 
Kisspeptin-10 Gq Diabetologia (2009) 52:855–862 
Vasopressin receptor 1B 
(V1B) 
Vasopressin Gq 




Serotonin Gq Diabetologia. (2016) 59:744-54 
Angiotensin II receptor 
type 1 (AT1) 
Angiotensin II Gq Diabetologia. (2006) 49:321-31 
Interleukin-6 receptor 
(IL-6R, CD126) 
Interleukin-6 Gq Diabetes. (2011) 60:537-47 
Olfactory receptors 15 
(OLFR15) 
Octanoic acid Gq Sci Rep. (2018) 8:1499 





Figure 1.5. Schematic diagram of a proinsulin-luciferase fusion protein and validation of 
luciferase activity as a proxy for secreted insulin 
(A) Diagram of proinsulin-luciferase fusion construct, showing Gaussia luciferase was inserted in 
C-peptide portion of proinsulin which was co-secreted with insulin. (B) Co-localization of 
luciferase and insulin. Luciferase activity upon high glucose with Oxo-M, positive control, and 
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Diabetes mellitus has grown to epidemic proportions and is considered a leading cause of death 
worldwide [1]. The etiology provides that a defect in pancreatic β-cell function significantly contributes 
to the pathogenesis of diabetes [2, 3]. Therefore, recent studies have focused on the improvement of β-
cell function via descriptions of new secretagogue in insulin secretion and the molecular mechanisms 
underlying these effects [4]. 
Glucose-stimulated insulin secretion (GSIS) in the pancreatic β-cell is mainly regulated by the 
glucose-stimulated triggering and amplifying pathways by a variety of factors [5]. The sequence of 
events that occurs as part of the triggering pathway are well established, i.e., glucose metabolism, 
closure of ATP-sensitive K+ channels, membrane depolarization, and Ca2+ entry through voltage-
dependent Ca2+ channels. Increased intracellular Ca2+ levels induce exocytosis of the insulin vesicle via 
activation of the exocytotic machinery [6]. The amplifying pathway is involved in both phases of GSIS 
and its potentiation in response to secretagogues such as non-glucose nutrients (e.g., free fatty acids and 
amino acids), hormones, and neuronal factors. A variety of substances such as serotonin (5-HT), 
nucleotides, amylin, or bivalent cations can also co-localize with insulin in secretory granules. These 
mediators are co-secreted with insulin upon glucose stimulation, primarily acting on surface receptors 
in both a paracrine and autocrine manner [7-10]. The majority of these extracellular signals are mediated 
via G protein-coupled receptors (GPCRs), which activate intracellular signaling by generating inositol 
triphosphate (IP3), diacylglycerols (DAGs), and cyclic adenosine 3 ,́5 -́ monophosphate (cAMP).  
Studies have shown that mice with GPCR-deficient in β-cells exhibit glucose intolerance and are 
unable to potentiate GSIS in response to corresponding ligands [11, 12]. Recently, these islet GPCRs 
have been regarded as potential targets for regulating insulin release, with several drugs already 
approved for the treatment of diabetes mellitus [13]. However, the exact mechanism underlying the 
amplifying effect has remained elusive and further studies are necessary to identify additional targets 
and mechanisms that involve the regulation of insulin secretion. 
Phospholipase Cβ (PLCβ) is one of the six enzyme subtypes (β, γ, δ, ε, ζ, and η) that play a 
principal role in GPCR-mediated signaling. PLCβ hydrolyzes membrane-bound phosphatidylinositol 
4,5-bisphosphate into IP3 and DAG, which are important secondary messengers in the downstream 
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signal pathway, regulating Ca2+ mobilization and protein kinase C (PKC) activation, respectively. The 
PLCβ family consists of four isozymes, PLCβ1 to β4, which share their primary structure; however, 
each isozyme differs in temporal and spatial expression, intracellular distribution, biological effect, and 
regulatory properties [14, 15].  
Emerging evidence has shown that PLCβs are considered crucial effectors in GPCR-mediated 
signaling transduction for potentiating insulin secretion. β-cell-specific ablation of G protein α-subunits 
Gαq and Gα11, which activate PLCβs, results in glucose intolerance and impaired insulin secretion. This 
indicates that PLCβs also contribute to the regulation of insulin secretion [16, 17]. However, previous 
studies have not focused on the roles of the specific PLCβ isozymes, and have only demonstrated the 
putative role of PLCβs in pancreatic β-cells, showing that blockade by non-selective PLC inhibitors, 
PKC inhibitors, or Ca2+ chelators leads to diminished insulin release [18, 19]. Additionally, it remains 
unclear which PLCβ regulates insulin secretion via which GPCR. 
To address the physiological role of PLCβs, we generated PLCβ isozyme-deficient mice in 
pancreatic β-cells. β-cell-specific PLCβ1 conditional knockout (cKO) mice (Plcb1f/f; Pdx1-CreERt2) 
showed impaired glucose tolerance due to deficiency in insulin secretion, with more severe phenotypes 
seen in Plcb1f/f; Pdx1-CreERt2 mice fed high-fat diets (HFDs). Furthermore, we discovered that 
particular GPCR-induced insulin release was PLCβ1-dependent. Taken together, the data presented here 
show that PLCβ1 is an important factor in the regulation of insulin secretion. 
 




Plcb1, 2, 3, and 4 cKO mice were generated by crossing Plcb1, 2, 3, or 4loxP/loxP mice (C57BL6/J 
background) with Pdx1-CreERt2 transgenic mice (C57BL6/J background). The LoxP sites of 
Plcb1loxP/loxP mice were flanked with exon 11, the LoxP sites of Plcb2loxP/loxP mice were flanked with 
exons 8–12, the LoxP sites of Plcb3loxP/loxP mice were flanked with exons 9–10, and the LoxP sites of 
Plcb4loxP/loxP mice were flanked with exon 6. Animals were backcrossed for at least eight generations 
onto a C57BL6/J background prior to use in these experiments. To induce the ablation of each Plcb 
isozyme gene, 4-week-old mice were injected with 2 mg of tamoxifen (Sigma, St. Louis, MO) 
intraperitoneally twice weekly for 2 weeks (four injections in total). Tamoxifen-treated male mice were 
used for all analyses. The genotypes of each group were confirmed by PCR. Genomic DNA from mice 
tails were used as templates for primers specific to the Plcb isozyme. To simulate a western diet, mice 
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were fed a HFD (60% kcal fat; #D12492; Research Diets, New Brunswick, NJ) from 6 weeks of age. 
The HFD study was performed with mice fed HFD for 10 weeks. Animals were maintained in a specific 
pathogen-free animal facility under a 12 h light/12 h dark cycle at a temperature of 21°C. The mice 
were allowed free access to water and food. All procedures were performed in accordance with the 





For the glucose tolerance test, animals were fasted overnight (16 h) and injected intraperitoneally 
with 2 mg/g of glucose. For the insulin tolerance test, animals were fasted for 6 h and intraperitoneally 
injected with 0.3 U/kg insulin. Blood glucose levels were assessed before injection and at 15, 30, 60, 
and 120 min after injection. Animals were treated intraperitoneally with a single dose of 5-HT (0.3 mg 
per mouse; Tocris Bioscience, Bristol, UK) and a single dose of bethanechol (2 µg/g; Sigma). Plasma 
glucose and insulin levels were measured at the indicated time points. Blood glucose levels were 
measured with a glucometer (Roche, Basel, Switzerland) and plasma insulin levels were estimated by 




Isolated islets were lysed in radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, 
Waltham, MA) containing a cocktail of proteinase inhibitors and phosphatase inhibitors according to 
the manufacturer’s recommendation. The total protein concentration was determined with a Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific). Total protein was separated with 8% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis. The separated proteins were transferred onto 
polyvinylidene fluoride membranes (Millipore, Burlington, MA), blocked with 5% (w/v) fat-free milk, 
and incubated with primary antibodies overnight at 4°C. After washing with Tris-buffered saline 
containing Tween 20, the membranes were incubated with horseradish peroxidase (HRP)-labeled 
secondary antibody and visualized using enhanced chemiluminescence reagents (GE Healthcare Life 
Sciences, Marlborough, MA). Anti-PLCB1 (sc-205), anti-PLCB2 (sc-206), anti-PLCB3 (sc-403), and 
anti-PLCB4 (sc-404) were obtained from Santa Cruz Biotechnology (Dallas, TX); anti-β-actin 
(GTX109639) was obtained from GeneTex (Irvine, CA). In apoptotic marker, anti-caspase3 and anti-






The pancreas was directly injected with 3 mL of 1 mg/mL collagenase (Roche) in Hank’s buffered 
saline solution (HBSS; Welgene, Gyeongsan-si, Republic of Korea) modified with 25 mM HEPES and 
adjusted to pH 7.4 with NaOH before addition of 0.25% (w/v) bovine serum albumin. The inflated 
pancreas was then dissected and incubated at 37°C for 15 min with manual shaking every 5 min. 
Samples were then filtered and washed with ice-cold modified HBSS three times, after which islets 
were separated by density gradient in Biocoll separating solution (Biochrom, Cambridge, UK). Islets 
were picked from the resulting layers and washed at least three times with ice-cold modified HBSS. 
Islets were then hand-selected under a dissecting microscope (SZ2-ST; Olympus, Tokyo, Japan), and 
cultured in RPMI-1640 medium at 37°C in a cell CO2 incubator overnight before the beginning of the 
experiments. 
 
Islet secretion assay 
 
After overnight recovery, size-matched medium islets and MIN6 cells were equilibrated with 
Krebs buffer solution (KRB; 137 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM 
CaCl2, 25 mM NaHCO3, and 10 mM HEPES, and adjusted to pH 7.4 with NaOH before addition of 0.5 
g/L bovine serum albumin) plus 2.8 mM glucose for 1 h. The islets were transferred to a 48-well plate 
and stimulated in 300 µL of Krebs buffer plus 2.8 mM and 16.7 mM glucose for 1 h (10–20 islets/well) 
containing ligands such as kisspeptin-10 (KP; Tocris Bioscience), [arg8][9]-vasopressin (AVP) acetate, 
5-HT, cholecystokinin-8 (CCK; Tyr[SO3]1)CCK-8), oxotremorine-M (OXO-M; DiscoveRx), and oleic 
acid (OA; Sigma). The supernatant was then collected, and insulin levels were normalized to the total 
protein level. The amount of insulin was quantified by ELISA using a mouse insulin ELISA kit 
(Shibayagi). All steps were performed in a CO2 cell incubator. 
 
Determination of intracellular Ca2+ 
 
Islets were washed twice, after which 10–20 islets per well were seeded onto 96-well optical-
bottom plates (Thermo Fisher Scientific) and loaded with fura-2-acetoxymethyl ester (Fura-2AM; final 
concentration 4 μM) in KRB for 45 min. Loaded islets were washed twice and used after a 15-min 
stabilization period. The plate was inserted into a microscope holder in contact with 100 μL of buffer at 
29 
 
37°C. Glucose (16.7 mM) and ligands (50 μM 5-HT and 20 μM OXO-M) were applied on top of the 
imaged islets, as indicated in the figure legends. The excitation signals were estimated using a 
fluorimeter to monitor fura-2AM fluorescence (motorized inverted microscope IX81; Olympus). 
 
Total insulin content measurement 
 
The total pancreas was placed in an acid–ethanol solution (1.5% HCl in 70% EtOH) and 
incubated overnight at −20°C. The pancreas was then homogenized and again incubated overnight at 
−20°C. The homogenized pancreas was centrifuged at 2,000 rpm for 15 min at 4°C, after which the 
aqueous solution was transferred and neutralized in 100 µL of acid–ethanol extract with 100 µL of 1M 
Tris (pH 7.5). The neutralized solution was measured by ELISA and protein content level was used as 
the internal control. 
 
Islet morphometry and immunohistochemistry 
 
Isolated pancreases were fixed in 10% neutral buffered formalin (Sigma) at 4°C overnight. 
Tissues were then embedded in paraffin, and 2 µm sections were sliced and mounted on glass slides. 
The sections were stained with hematoxylin and eosin (H&E) using standard procedures or 
immunostained with PLCβ1 (ab185724; Abcam), insulin antibody (ab6995; Abcam), glucagon 
antibody (G2654; Sigma), Somatostatin antibody (#13-2366; American Research Products Inc., 
Waltham, MA) and Ki-67 antibody (ab15580; Abcam). Sections were revealed using HRP- or Alexa 
dye-conjugated secondary antibodies (Invitrogen, Carlsbad, CA). For insulin positivity, the islet insulin 
immunoreactive cross-sectional area were analyzed and calculated using ImageJ software (NIH). 
 
Quantitative real-time PCR 
 
RNA was isolated with TRIzol reagent and cDNA was synthesized with a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Quantitative real-time PCR (qRT-
PCR) was performed using Prime Q-Mastermix (Genet Bio, Daejeon, Republic of Korea) and the 
LightCycler 480 II Real-Time PCR system (Roche). Relative gene expression was calculated using the 






Mice were transcardially perfused with a 4% paraformaldehyde and post-fixed overnight at 4°C. 
Fixed brains were placed in 30% sucrose in phosphate buffered saline (PBS) overnight and the brain 
was sliced into 40μm thickness using vibrating blade microtome. Freely floating sections were rinsed 
with PBS and permeabilized in PBS containing 0.2% Triton X-100 for 1 h at room temperature (RT). 
After permeabilization, brain sections were blocked with 10% normal goat serum in PBS for 1 h. For 
investigation of PLCβ1 expression, brain sections were incubated with anti-PLCβ1 primary antibody 
(1:200, sc-5291; Santa Cruz Biotechnology) at 4°C for 12 h followed by incubation for 1 h at RT with 
goat anti-mouse Alexa-488 conjugated IgG (1:500, Invitrogen). All stained sections were 
counterstained with Hoechst 33258 (#94403; Sigma) and mounted with mounting medium (F4680; 




Food intake were determined using Comprehensive Lab Animal Monitoring System (CLAMS; 
Columbus Instruments, Columbus, OH, USA). Mice were individually placed in each cages of the 
calorimetric system which were kept at room temperature, 21°C. Measurements were proceeded for 72 
h. The mice were free to access to water and foods. 
 
Generation of stable cell lines 
 
Plcb1-deleted MIN6 cell lines were generated by transfection of DNA construct expressing 
sgRNA (ex30; CCGATCGTACATCCAGGAGGTGG) plus Cas9 (ToolGen, Seoul, Republic of Korea) 
using lipofectamine 2000 reagent (Thermo Fisher Scientific) according to the protocol from 
manufacturer. The cells were selected with hygromycin (200μg/mL, Sigma) in DMEM medium 
containing 10% FBS for 4 days. The PLCβ1 reconstitution was achieved using lentiviral vector 
expressing PLCβ1 (EX-Mm20972-Lv157 plasmid; GeneCopoeia, Rockville, MD) in Plcb1-deleted 




Data were analyzed using a two-tailed unpaired sample t-test, with ***p < 0.001, **p < 0.01, and 
31 
 




PLCβ1, 3, and 4 isozymes are moderately expressed in pancreatic β-cells 
 
PLCβs have been shown to be major effector molecules in the pancreatic β-cell signaling cascade 
and have been implicated in the potentiation of insulin release [20, 21]. The four PLCβ isozymes, 
PLCβ1 to β4, differ in expression pattern and regulation. However, studies of PLCβ isozyme expression 
patterns have been controversial [22-24], with additional investigations necessary to determine the 
expression levels of individual PLCβ isozymes. First, to confirm the PLCβ isozyme expressed in 
pancreatic β-cells, we assessed PLCβ isozyme expression patterns in MIN6 cells, a mouse pancreatic 
β-cell line, and in mouse primary pancreatic islets in which β-cells are the major cell type by Western 
blotting (Figure 2.1A) and qRT-PCR (Figure 2.1B, C). PLCβ1 is enriched in the cerebral cortex and 
hippocampus [25], whereas PLCβ4 is highly expressed in the cerebellum [26]. Expression of PLCβ2 is 
largely restricted to hematopoietic cells [27], while PLCβ3 is ubiquitously expressed [28]. Indeed, 
PLCβ1 and PLCβ4 were highly expressed in the brain, while PLCβ2 was limited to the thymus enriched 
origin of hematopoietic cells. In the case of mouse pancreatic β-cells in the present study, PLCβ1, β3, 
and β4 expressions were apparent; however, PLCβ2 was detected at only trace levels in MIN6 cells and 
pancreatic islets. Taken together, these results led us to further investigate PLCβ isozymes as a potential 
regulator of β-cell function. 
 
Each PLCβ isozyme was selectively ablated in adult pancreatic β-cells 
 
To gain insight into the physiological role of each PLCβ isozyme in adult pancreatic β-cells, we 
employed the conditional gene knockout system to eliminate each Plcb isozyme gene in mature β-cells. 
After embryonic day 16.5, pancreas/duodenum homeobox protein 1 (Pdx1) is specifically expressed in 
the β-cell compartment in pancreatic islets [29]. Thus, we generated PLCβ isozyme cKO mice in adults 
by mating floxed/floxed mice for each PLCβ isozyme with mice carrying the Pdx1-creERt2 transgene, 
in which tamoxifen induced activation of Cre recombinase via the Pdx1 promoter (Figure 2.2A). Cre 
activation was induced in 4-week-old male mice via twice weekly intraperitoneal injections of 
tamoxifen for 2 weeks. After 1 week of tamoxifen injection, reduced expression of each PLCβ isozyme 
was confirmed in protein extracts from islets prepared from control and PLCβ isozyme cKO mice 
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(Figure 2.2B). This finding indicated that PLCβ isozyme deletion was restricted to the β-cell area and 
any alternation of phenotype in PLCβ cKO mice was derived from the deletion of the PLCβ isozyme in 
pancreatic β-cells. 
 
Loss of PLCβ1 in adult pancreatic β-cells resulted in impaired glucose tolerance 
 
Next, we assessed glucose homeostasis in the PLCβ cKO mice. Before and after tamoxifen 
injection, all mice carrying Pdx1-creERt2 showed similar body weights (Figure 2.8A), as well as fasting 
and re-feeding blood glucose levels, as the control group (Figure 2.8B). A glucose tolerance test was 
used to measure the dynamics of glucose response in mice (Figure 2.3A–D). Following intraperitoneal 
injection of glucose, only the Plcb1f/f; Pdx1-CreERt2 mice exhibited a lower ability to clear glucose 
from the blood than the Plcb1f/f mice, which resulted in glucose intolerance (Figure 2.3A); the other 
groups showed similar glucose tolerances to that of the control group (Figure 2.3B–D). Despite glucose 
intolerance, Plcb1f/f; Pdx1-CreERt2 mice showed similar insulin sensitivity to that of the Plcb1f/f mice, 
as shown by the insulin tolerance test, which suggested that impaired glucose tolerance was not caused 
by insulin sensitivity (Figure 2.9A). Thus, the Plcb1 gene is required for normal glycemic control. 
 
Plcb1f/f; Pdx1-CreERt2 mice displayed altered insulin secretion to glucose stimulation 
 
To test the underlying cause of glucose intolerance, we measured plasma insulin levels in Plcb1f/f; 
Pdx1-CreERt2 mice after overnight fasting as well as 15 and 30 min after intraperitoneal glucose 
challenge. Plasma insulin levels of Plcb1f/f; Pdx1-CreERt2 mice were lower than that of Plcb1f/f mice, 
leading to increased plasma glucose levels (Figure 2.4A, B). 
The defect in GSIS likely underlies the impaired glucose tolerance. To study the β-cell 
autonomous effect, and to determine whether Plcb1f/f; Pdx1-CreERt2 islets showed a corresponding 
decrease in GSIS, we performed GSIS assays using islets isolated from Plcb1f/f and Plcb1f/f; Pdx1-
CreERt2 mice. At basal glucose levels (2.8 mM), insulin levels secreted from Plcb1f/f; Pdx1-CreERt2 
islets were similar to Plcb1f/f islets. After high glucose stimulation (16.7 mM) for 1 h, Plcb1f/f; Pdx1-
CreERt2 islets secreted lower insulin than that of the Plcb1f/f islets (Figure 2.4C). An increase in 
intracellular calcium ([Ca2+]i) is critical for regulated insulin exocytosis [30]. We measured the [Ca2+]i 
level in primary islets isolated from the Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice using the fluorescent 
Ca2+ indicator Fura-2AM. Under high glucose stimulation, [Ca2+]i levels were dramatically increased 
in primary islets; however, the elevation of [Ca2+]i by glucose was markedly lower in primary islets 
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from Plcb1f/f; Pdx1-CreERt2 mice than in islets from the Plcb1f/f mice (Figure 2.4D). This abnormal 
Ca2+ response in Plcb1f/f; Pdx1-CreERt2 mice islets may have caused the impaired GSIS. These results 
suggest that PLCβ1 affects pancreatic β-cell function, with a potential role in mediating insulin secretion. 
 
Insulin production and islet morphological characteristics were normal in Plcb1f/f; Pdx1-CreERt2 
mice 
 
Impaired insulin secretion was associated with abnormal insulin synthesis or pancreatic β-cell 
architecture [31, 32]. First, we confirmed the expression of PLCβ1 by performing 
immunohistochemistry analysis. Consistent with the previously published data [22, 33], PLCβ1 was 
localized in both nucleus and cytosol in islet cells and was also detected in the nucleus in exocrine cells. 
However, α-cells and δ-cells were either negative or weakly positive for PLCβ1 staining (Figure 2.10). 
Double staining for insulin and PLCβ1 on the pancreas sections indicated that PLCβ1 expression was 
selectively eliminated in the β-cell compartment in the pancreas of tamoxifen-treated mouse (Figure 
5A). Also, mRNA levels of PLCβ1 were diminished in Plcb1f/f; Pdx1-CreERt2 islets relative to Plcb1f/f 
islets (Figure 2.5B). We then examined whether reduced total insulin content in the pancreas might 
cause glucose intolerance and impaired insulin secretion. The total insulin content in the pancreas from 
Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice was measured by ELISA and the insulin mRNA levels were 
determined by qRT-PCR from islets isolated from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice (Figure 
2.5B, C). The total insulin content was similar in the pancreases of the Plcb1f/f and Plcb1f/f; Pdx1-
CreERt2 mice and there were no differences in insulin mRNA levels (Ins1 and Ins2) between Plcb1f/f 
and Plcb1f/f; Pdx1-CreERt2 islets in which the Plcb1 gene was stably ablated. In H&E-stained sections, 
Plcb1f/f; Pdx1-CreERt2 islets appeared similar in shape, size, and distribution in the pancreas compared 
to Plcb1f/f islets (Figure 2.5D). Furthermore, pancreatic β-cells from the Plcb1f/f and Plcb1f/f; Pdx1-
CreERt2 mice had similar areas (Figure 2.5E). Histological analysis revealed no pathological clues in 
Plcb1f/f; Pdx1-CreERt2 islets. These results indicate that insulin secretion dysfunction is not caused by 
defects in insulin synthesis and β-cell architecture. 
 
GPCR-dependent augmentation of GSIS was selectively diminished in Plcb1-deficient pancreatic 
islets 
 
In pancreatic β-cells, Gq-protein coupled receptors (GqPCRs) are involved in regulating 
potentiation of GSIS, with PLCβs acting as principal effector molecules downstream of GPCRs [16, 
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34]. Our initial findings indicated that PLCβ1 was engaged in the regulation of GSIS. To examine 
whether PLCβ1 was also associated with GqPCR-dependent potentiation of GSIS, we performed an 
insulin secretion assay using islets isolated from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice. Isolated 
islets were incubated with ligands known to augment insulin release via GqPCRs, including AVP, 5-HT, 
KP, CCK, OXO-M, and OA, in the presence of high glucose concentrations (16.7 mM) [13]. Treatment 
with these ligands led to a significant enhancement of GSIS in islets from Plcb1f/f mice; however, these 
potentiation effects were diminished in the Plcb1f/f; Pdx1-CreERt2 islets for AVP, 5-HT, and KP (Figure 
2.6A). These results indicated that the elimination of Plcb1 in pancreatic β-cells caused defects in the 
potentiation of specific GqPCR-dependent insulin secretion.  
PLCβ1 transduces intracellular signaling from specific 5-HT receptors in the superior temporal 
gyrus, leading to the pathogenesis of schizophrenia [35, 36]. In pancreatic β-cells, 5-HT potentiates 
GSIS by increasing the glucose-evoked Ca2+ response [37]. We further explored 5-HT-mediated insulin 
secretion in Plcb1f/f; Pdx1-CreERt2 mice. 5-HT induced an increase in [Ca2+]i that led to potentiation 
of insulin secretion; however, the 5-HT-dependent effect was attenuated in Plcb1f/f; Pdx1-CreERt2 islets 
compared to Plcb1f/f islets, which resulted in altered insulin secretion (Figure 2.6B). In contrast, 
exposure to OXO-M, a muscarinic receptor agonist, triggered similar Ca2+ peaks in Plcb1f/f; Pdx1-
CreERt2 and Plcb1f/f islets (Figure 2.6C). Next, we intraperitoneally injected 5-HT into Plcb1f/f and 
Plcb1f/f; Pdx1-CreERt2 mice and measured the changes in plasma insulin and glucose at serial time 
points. Following 5-HT injection, there was a clear trend toward increased plasma insulin levels with 
decreased plasma glucose levels; however, the augmentation of 5-HT-induced insulin secretion 
disappeared in Plcb1f/f; Pdx1-CreERt2 mice (Figure 2.6D). Additionally, we performed intraperitoneal 
injections of bethanechol, a nonsubtype-selective muscarinic agonist, in Plcb1f/f and Plcb1f/f; Pdx1-
CreERt2 mice. After bethanechol treatment, no significant change in plasma insulin and glucose levels 
were observed between groups, consistent with our ex vivo results (Figure 2.6E). These findings indicate 
that PLCβ1 is required for GSIS in a selective GqPCR-dependent manner, particularly as a 5-HT 
receptor, in pancreatic β-cells. 
 
High-fat diet caused severe defects in glucose homeostasis in Plcb1f/f; Pdx1-CreERt2 mice 
 
Microarray analysis revealed that PLCβ1 expression in pancreatic β-cells was significantly lower 
in patients with type 2 diabetes than in non-diabetic subjects (Figure 2.11, p = 0.01), implying that 
PLCβ1 might contribute to the pathophysiology of type 2 diabetes [38]. To test these effects, Plcb1f/f 
and Plcb1f/f; Pdx1-CreERt2 mice were challenged with a HFD that mimicked the status of the human 
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metabolic syndrome known to cause an increased functional response in pancreatic β-cells. HFD 
induced a significant, progressive increase in body weight in both Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 
mice, although no significant differences in weight gain were observed between groups (Figure 2.7A). 
In addition, islet morphology and β-cell proportion were not distinguishable between the two groups 
(Figure 2.7B). Next, we performed the glucose tolerance test to analyze glucose homeostasis in Plcb1f/f; 
Pdx1-CreERt2 mice during HFD intake. Plcb1f/f; Pdx1-CreERt2 mice receiving the HFD exhibited 
marked defects in glucose clearance in the blood relative to Plcb1f/f mice (Figure 2.7C), with no change 
in insulin sensitivity (Figure 2.9B) or total insulin content (Figure 2.7D) between groups. This 
pronounced deficiency in glucose tolerance was correlated with reduced plasma insulin levels, which 
led to elevated glucose levels in Plcb1f/f; Pdx1-CreERt2 mice (Figure 2.7E). Correspondingly, the GSIS 
assay in cultured islets from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice fed a HFD showed that the 
stimulatory effect of high glucose was lower in Plcb1f/f; Pdx1-CreERt2 islets than in those of Plcb1f/f 
islets (Figure 2.7F). Thus, PLCβ1 is necessary to maintain normal insulin secretion from β-cells and 
this mechanism is more prominent in a HFD-induced state. 
 
2.4. Conclusion and Discussion 
 
It has been shown that progressive β-cell dysfunction, defined as the inability to secrete insulin 
in response to high glucose levels, is a leading pathophysiological sign of type 2 diabetes. The β-cell 
mechanism for sensing glucose and releasing insulin is mediated by specialized transporters and 
sequential enzymes [6]. While these mechanisms for GSIS is well established, the underlying factors 
that mediate GSIS remain poorly understood. 
A recent study showed that PLCβ1 levels in β-cells of patients with type 2 diabetes was lower 
than in those of non-diabetic subjects. This finding suggests a possible function for PLCβ1 in the 
alteration of insulin secretion and pathogenesis of type 2 diabetes [38]. Interestingly, the potency of the 
insulin secretory response of mouse islets is lower than that of rat islets due to the lower expression of 
PLCβ1 and PLCδ1 in mice, indicating a critical role of PLCβ1 in β-cell function [24]. Furthermore, the 
silencing of nuclear PLCβ1 results in reduced GSIS with decreased mRNA expression of peroxisome 
proliferator-activated receptor-γ in the INS-1 rat insulinoma cell line [33]. However, further studies 
exploring the function of the PLCβ isozyme in pancreatic β-cells ex vivo and in vivo are required to 
understand the precise mechanisms controlling insulin secretion in response to different secretagogues. 
Here, we demonstrated that PLCβ1 enabled β-cells to manage their highly specialized function, 
particularly insulin secretion. We demonstrated that the conditional ablation of PLCβ1 in pancreatic β-
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cells of adult mice led to glucose intolerance due to decreased insulin secretion without altering insulin 
content or affecting β-cell architecture. In addition, the Pdx1 promoter showed restricted Cre activity 
primarily within the hypothalamus and Cre-mediated recombination in hypothalamus region could be 
involved in regulation of food intake or body weight [39]. Although PLCβ1 expression was decreased 
in hypothalamus, Plcb1f/f; Pdx1-CreERt2 mice showed no alteration in food intake or body weight 
(Figure 2.12A, B). The impaired insulin secretion in Plcb1f/f; Pdx1-CreERt2 mice was attributed to an 
intrinsic defect in β-cells, as isolated islets from these mice exhibited lower GSIS than those of Plcb1f/f 
mice. Our data showed that PLCβ1 exerted its effects exclusively via GSIS augmentation, making it 
important to determine the mechanism through which glucose induces PLCβ1-mediated insulin 
secretion. Glucose can stimulate the production of inositol phosphates in pancreatic islets, and PLCβ is 
a class of enzymes involved in phosphoinositide hydrolysis. Therefore, glucose is likely to stimulate 
PLC activity, leading to the accumulation of inositol trisphosphate and inositol tetrakisphosphate [40, 
41]. Despite a lack of evidence supporting the involvement of mediators, glucose may couple the PLCβ-
mediated production of inositol phosphates and insulin secretion [17, 42]. 
Here, we confirmed that PLCβ1 contributed to 5-HT-, VAP-, and KP-dependent insulin secretion. 
In pancreatic islets, innervation and vascularization are important mechanisms in the regulation of 
insulin secretion. Notably, modulators such as 5-HT, released from pancreatic nerve endings, and 
vasopressin or kisspeptin, released from blood capillaries, activate PLCβ-coupled G proteins and 
augment insulin release under high glucose conditions. Moreover, β-cells co-secrete various substances, 
including 5-HT, with insulin under high glucose stimulation. These mediators from blood, nerve, and 
insulin vesicles could activate GPCR/PLCβ1 signaling in a paracrine and autocrine manner, leading to 
increased insulin secretion [7-10]. In particular, 5-HT-dependent insulin secretion is more prominent 
during pregnancy. Pregnancy results in increased β-cell proliferation and GSIS to compensate for the 
enhanced insulin demand through 5-HT signaling [37, 43]. Indeed, maternal lactogens significantly 
induce the synthesis and secretion of 5-HT, which activates the Htr2b receptor on β-cells to augment 
GSIS [44]. In male adult Plcb1f/f; Pdx1-CreERt2 mice, there was no remarkable change in β-cell 
proliferation and β-cell turnover (Figure 2.13A, B). However, PLCβ1 signaling that regulates GSIS 
through serotonergic pathways might also be active during pregnancy, and PLCβ1 could be the genetic 
cause of gestational diabetes, which has great potential for developing into type 2 diabetes mellitus [45]. 
GPCRs can bind specific PLCβs and modulate intracellular signaling by binding distinct partners, 
such as A-kinase anchoring proteins and postsynaptic density disc-large ZO-1 proteins [46, 47]. 




In this study, alterations to specific ligands, such as CCK, OXO-M, and OA, did not produce any 
differences in insulin secretion between pancreatic islets from Plcb1f/f; Pdx1-CreERt2 and Plcb1f/f mice. 
One possible explanation for this distinction is functional compensation. Although there was no 
compensatory upregulation of PLCβ isozymes (Figure 2.14A, B), due to a shared primary structure and 
similar enzymatic activity, other still expressed PLCβ isozymes might be engaged with these GqPCRs. 
In addition, this finding indicates the involvement of G protein families other than Gq, such as the Gs 
family [48, 49]. Indeed, treatment of pancreatic islets with carbamylcholine, a muscarinic receptor 
agonist, and CCK results increased cAMP levels, which can enhance insulin secretion, indicating that 
they could control insulin secretion in a PLCβ1-independent manner [50]. In fact, CCK1 receptors have 
been reported to couple to both Gq and Gs. The CCK1-Gs pathway has been shown to regulate insulin 
secretion under high glucose conditions, while CCK1-Gq signaling is able to regulate insulin secretion 
under low glucose conditions [51]. 
The glucose-stimulated [Ca2+]i increase in β-cells requires Ca2+ influx via membrane 
depolarization and activation of L-type calcium channels. Besides IP3-mediated Ca2+ efflux from the 
endoplasmic reticulum (ER), PLCβ can contribute to further [Ca2+]i increases via its function as an 
important upstream signaling molecule for activation of store-operated channels (SOCs) and transient 
receptor potential channels (TRPCs) [52]. Depletion of ER Ca2+ stores via the IP3 receptor leads to 
activation of SOCs on the plasma membrane. Local reduction of PIP2 and increased DAG directly 
facilitate activation of TRPC3 [53], with PKC also activating nonselective cation channels, increasing 
[Ca2+]i [18]. However, despite these observations, further studies are required about a direct association 
between the PLCβ pathway and activation of Ca2+ channels. 
Normal pancreatic β-cells have the capacity to secrete adequate levels of insulin necessary to 
compensate for increased insulin demands under conditions of HFD-associated insulin resistance [54]. 
Indeed, in islets isolated from mice fed HFD, pancreatic islets were expanded and secreted insulin levels 
were augmented, about 0.5 ng/µg protein/h, as compared to those fed normal chow diet (NCD), about 
0.1 ng/µg protein/h. Also, basal insulin levels were increased in HFD-fed mice, around 0.5 ng/ml, as 
compared to NCD-fed mice, around 0.2 ng/ml. In Plcb1f/f; Pdx1-CreERt2 mice, HFD-feeding induced 
defects in glucose homeostasis. Similar to the role of PLCβ1 in regulating insulin secretion in normal 
Plcb1f/f; Pdx1-CreERt2 mice, the HFD-fed Plcb1f/f; Pdx1-CreERt2 mice also developed severe glucose 
intolerance due to a deficiency in insulin secretion. In addition, we confirmed that reduced insulin 
secretion was recovered in adding PLCβ1 back in MIN6 cell lines (Figure 2.15A, B). These result 
strongly support that effect on reduced insulin secretion was due to the PLCβ1 deletion and PLCβ1 can 

















Figure 2.1. Expression profile of PLCβ isozymes in pancreatic β-cells 
(A) Western blot analysis showing PLCβ isozyme proteins from extracts of MIN6 cells and isolated 
islets from wild type mice (C57BL6/J, 8 weeks old). (B, C) qRT-PCR analysis showing relative 
PLCβ isozyme mRNA levels in total RNA from MIN6 cells and islets isolated from wild type mice. 




























Figure 2.2. Inducible ablation of PLCβ isozymes in adult pancreatic β-cells 
(A) Graphical diagram of adult Plcb1, 2, 3, or 4f/f mice carrying the Pdx1-creERt2 transgene 
injected with tamoxifen to induce β-cell-specific deletion of PLCβ1, 2, 3, or 4 isozymes. (B) 
Western blot analysis showing the reduction in PLCβ isozyme protein contents from extracts of 

























Figure 2.3. Impaired glucose tolerance in Plcb1f/f; Pdx1-CreERt2 mice 
(A) Glucose tolerance test (2 mg glucose/g, intraperitoneal injection) for tamoxifen-treated Plcb1f/f 
and Plcb1f/f; Pdx1-CreERt2 mice (n = 6 per group), (B) Plcb2f/f and Plcb2f/f; Pdx1-CreERt2 mice 
(Plcb2f/f, n = 12 vs. Plcb2f/f; Pdx1-CreERt2, n = 8), (C) Plcb3f/f and Plcb3f/f; Pdx1-CreERt2 mice 
(Plcb3f/f, n = 7 vs. Plcb3f/f; Pdx1-CreERt2, n = 10), and (D) Plcb4f/f and Plcb4f/f; Pdx1-CreERt2 














Figure 2.4. Defect in GSIS in Plcb1f/f; Pdx1-CreERt2 mice 
(A) Plasma insulin and (B) glucose levels after overnight fasting (16 h), 15 min, and 30 min post 
glucose injection in Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice (Plcb1f/f, n = 5 vs Plcb1f/f; Pdx1-
CreERt2, n=7). (C) Secreted insulin levels from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 islets. The 
results represent five independent experiments with islets from three mice per genotype. (D) 
Intracellular Ca2+ influx in isolated mouse islets from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice. 
Pseudo-colored image of the fura-2AM fluorescence ratio (F340/F380) following high glucose 
treatment (left panel), the change in F340/F380 (middle panel, n = 11 per group), and the maximum 
change in F340/F380 (right panel, n = 11 per group). Error bars represent ± SEM. ***p < 0.001 and 























Figure 2.5. Normal insulin production and islet morphology 
(A) Pancreatic sections stained with insulin and PLCβ1 antibodies. (B) mRNA expression of insulin 
genes from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 islets (three independent experiments with pooled 
islets from three mice per group). (C) Total insulin content of the pancreas (n = 4 per group). (D) 
Pancreatic sections from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice stained with H&E. (E) Insulin 
staining of pancreatic sections and quantification of β-cell area in Plcb1f/f and Plcb1f/f; Pdx1-
CreERt2 mice (four to five islets were analyzed from the Plcb1f/f, n = 4 vs. Plcb1f/f; Pdx1-CreERt2, 
n = 5). Scale bars, low magnification: 200 µm, high magnification: 50 µm. Error bars represent ± 






















Figure 2.6. Decreased selective GqPCR-induced insulin release in Plcb1f/f; Pdx1-CreERt2 islets 
(A) Selective augmentation of insulin secretion in pancreatic islets. Isolated pancreatic islets 
prepared from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 were incubated for 1 h at 37°C in Krebs solution 
containing 16.7 mM glucose. In addition, the incubation medium contained one of the following 
ligands: AVP (5 μM), 5-HT (50 μM), KP (1 μM), CCK (500 nM), OXO-M (20 μM), and OA (10 
μM). Supernatants were analyzed by ELISA. Data shown are representative of five independent 
experiments with islets from six to eight mice per genotype. (B) Pseudo-colored image of the fura-
2AM fluorescence ratio (F340/F380, upper panel), the change in F340/F380 (left panel), and the 
maximum change in the F340/F380 response (right panel) to 5-HT treatment (50 μM, n = 20 per 
group) and (C) to OXO-M treatment (20 μM, n = 25 per group). Blood glucose and insulin levels 
of Plcb1f/f; Pdx1-CreERt2 mice and Plcb1f/f littermates after receiving (D) a single dose of 5-HT 
(0.3 mg per mouse, Plcb1f/f, n = 5 vs. Plcb1f/f; Pdx1-CreERt2, n = 6) and (E) a single dose of 
bethanechol (2 µg/g, intraperitoneal injection, Plcb1f/f, n = 6 vs. Plcb1f/f; Pdx1-CreERt2, n = 7). 
Plasma glucose and insulin levels were measured at the indicated time points. Scale bar: 400 µm. 







Figure 2.7. Impaired insulin secretion in Plcb1f/f; Pdx1-CreERt2 mice fed a HFD 
(A) Body weight during HFD feeding (Plcb1f/f, n = 5 vs. Plcb1f/f; Pdx1-CreERt2, n = 4). (B) 
Pancreatic sections from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice stained with H&E and insulin 
staining of pancreatic sections (20 weeks old mice in figure 7A). (C) Glucose tolerance test (2 mg 
glucose/g, intraperitoneal injection, n = 7 per group). (D) Total insulin content of pancreas (n = 4 
per group). (E) Plasma glucose and insulin levels from Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice (n 
= 5–7 per group) post glucose injection. (F) Secreted insulin levels from Plcb1f/f and Plcb1f/f; Pdx1-
CreERt2 islets (three independent experiments with pooled islets from three mice per group). Scale 
bars, low magnification: 200 µm, high magnification: 50 µm. Error bars represent ± SEM. ***p < 





Figure 2.8. Similar body weight and fasting and re-feeding glucose levels between 
control and PLCβ cKO mice following tamoxifen treatment 
(A) Body weight of Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice (Plcb1f/f, n = 7 vs. Plcb1f/f; 
Pdx1-CreERt2, n = 8), Plcb2f/f and Plcb2f/f; Pdx1-CreERt2 mice (Plcb2f/f, n = 12 vs. 
Plcb2f/f; Pdx1-CreERt2, n = 9), Plcb3f/f and Plcb3f/f; Pdx1-CreERt2 mice (Plcb3f/f, n = 6 
vs. Plcb3f/f; Pdx1-CreERt2, n = 7), and Plcb4f/f and Plcb4f/f; Pdx1-CreERt2 mice (Plcb4f/f, 
n = 6 vs. Plcb4f/f; Pdx1-CreERt2, n = 5) mice. (B) Fasting and re-feeding glucose levels of 
Plcb1f/f and Plcb1f/f; Pdx1-CreERt2 mice (Plcb1f/f, n = 7 vs. Plcb1f/f; Pdx1-CreERt2, n = 
8), Plcb2f/f and Plcb2f/f; Pdx1-CreERt2 mice (Plcb2f/f, n = 8 vs. Plcb2f/f; Pdx1-CreERt2, n 
= 9), Plcb3f/f and Plcb3f/f; Pdx1-CreERt2 mice (Plcb3f/f, n = 7 vs. Plcb3f/f; Pdx1-CreERt2, 
n = 8), and Plcb4f/f and Plcb4f/f; Pdx1-CreERt2 mice (Plcb4f/f, n = 6 vs. Plcb4f/f; Pdx1-





Figure 2.9. Normal insulin sensitivity in Plcb1f/f; Pdx1-CreERt2mice fed a normal chow diet 
and HFD 
(A) Insulin tolerance test (0.3 U/kg) for control and Plcb1f/f; Pdx1-CreERt2 mice fed a normal 
chow diet (Plcb1f/f, n = 6 vs. Plcb1f/f; Pdx1-CreERt2, n = 7) and (B) Plcb1f/f and Plcb1f/f; Pdx1-




Figure 2.10. PLCβ1 protein expression in α-cell and δ-cells in pancreatic islets from control 
and Plcb1f/f; Pdx1-CreERt2 islets  




Figure 2.11. Reduced PLCβ1 expression in human β-cells from type 2 diabetes patients 
compared to normal subjects 
PLCβ1 expression in human β-cells from normal and type 2 diabetes patients (DM) plotted as 




Figure 2.12. Reduced PLCβ1 expression in hypothalamus results in no alteration in food 
intake 
(A) Brain sections stained with PLCβ1 antibodies in hypothalamus. (B) Absolute food intake (n = 
6 per group). 3V; Third ventricle. Scale bars, low magnification: 50 µm, high magnification: 100 





Figure 2.13. No change in β-cell proliferation and β-cell turnover in Plcb1f/f; Pdx1-CreERt2 
islets 
(A) Pancreatic sections stained with insulin and Ki-67 antibodies. (B) Western blot analysis 
showing apoptotic protein contents from extracts of isolated islets from Plcb1f/f and Plcb1f/f; 




Figure 2.14. PLCβ isozyme expression in each PLCβ isozyme conditional knockout islets  
(A) Western blot and (B) qRT-PCR analysis showing all PLCβ isozyme contents from extracts of 
isolated islets from each PLCβ isozyme conditional knockout mice following tamoxifen treatment. 




Figure 2.15. Reconstitution of PLCβ1 expression to rescue cells from abnormal insulin 
secretion  
(A) Western blot analysis showing the PLCβ1 protein contents and (B) Secreted insulin level from 
PLCβ1-rescued MIN6 cell lines under high (16.7mM) glucose condition (n = 3). Error bars 





Gene Sequence (5’-3’) 
Plcb1-F AGA TCA GCG AGG ACA GCA AT 
Plcb1-R GCC CAG GCA GTG ATA TTT GT 
Plcb3-F TTC GCC CTG ATG AGT TTC CC 
Plcb3-R AGC ACT TCG TTG AGT CTC GG 
Plcb4-F CCA CCG ACA CCA TAC GGA AA 
Plcb4-R GGA GAT GTG TCG GTA GCC T 
Ins-1-F GAC CAG CTA TAA TCA GAG ACC ATC 
Ins-1-R GTA GGA AGT GCA CCA ACA GG 
Ins-2-F GGC TTC TTC TAC ACA CCC AT 
Ins-2-R CCA AGG TCT GAA GGT CAC CT 
36b4-F TGG CCA ATA AGG TGC CAG CTG CTG 
36b4-R CTT GTC TCC AGT CTT TAT CAG CTG CAC 
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Zafirlukast promotes insulin secretion by increasing calcium influx through 




Zafirlukast is a prescription drug used for the treatment of asthma. Zafirlukast blocks the action 
of leukotrienes, especially leukotriene type D4 and E4, on cysteinyl leukotriene receptor 1 (CysLTR1), 
alleviating breathing passage inflammatory responses such as airway constriction and mucus secretion 
in the lungs [1, 2]. Pranlukast and montelukast, two other leukotriene antagonists, also selectively 
inhibit activation of CysLTR1 [3]. CysLTR1 antagonists are considered safe and their anti-inflammatory 
properties have been well documented [4-6]. However, patient with mild asthma who received 
zafirlukast treatment (20 mg twice daily) showed adverse hypoglycemic effects compared with the 
placebo control [7]. The mechanism underlying the hypoglycemia is unclear and the functional role of 
zafirlukast in pancreatic β-cells has not been elucidated. 
Insulin is the major hormone that lowers glucose levels in the body and insulin secretion is tightly 
regulated to manage blood glucose levels [8]. Glucose is transported into β-cells by glucose transporters 
and metabolized to produce ATP. An increase in the ATP:ADP ratio results in closure of ATP-sensitive 
K+ channels (KATP channels), membrane depolarization, and activation of voltage-dependent Ca2+ 
channels. An increase in the intracellular calcium ([Ca2+]i) level induces exocytosis of insulin vesicles 
by a Ca2+-binding membrane protein located in the membrane of the docked granule [9]. Insulin 
secretion can be increased in the presence of hormonal and neuronal factors such as glucagon-like 
peptide and serotonin [10]. 
The effects of zafirlukast on insulin secretion have not been examined. Here, we investigated the 
effect of zafirlukast on insulin release in the regulation of [Ca2+]i levels in pancreatic β-cells. Among 
montelukast, pranlukast, and zafirlukast, only zafirlukast treatment induced increases in insulin 
secretion and [Ca2+]i in MIN6 cells, triggering phosphorylation of Ca2+/calmodulin-dependent protein 
kinase II (CaMKII), protein kinase B (AKT), and extracellular signal-regulated kinase (ERK). This 
zafirlukast-dependent stimulation in insulin release was also observed in mouse primary pancreatic 
islets. However, pranlukast had no effect on the [Ca2+]i level or insulin secretion, and montelukast 
inhibited insulin secretion and the phosphorylation of related signaling molecules. In pancreatic β-cells, 
the zafirlukast-dependent stimulation of insulin release was suppressed by nifedipine, a dihydropyridine 
(DHP) L-type Ca2+ channel (L-VDCC) antagonist, suggesting that L-VDCCs are involved in the 
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underlying mechanism. Moreover, treatment of mice with zafirlukast resulted in a glucose-lowering 
response followed by promotion of insulin secretion in vivo. These findings reveal a novel function of 
zafirlukast in pancreatic β-cells [11]. 
 




All animal experiments were performed in accordance with Ulsan National Institute for Science 
and Technology Guide for the Care and Use of Laboratory Animals. C57BL/6J mice were maintained 
in animal facility on a pathogen-free facility under a 12-h light/dark cycles at temperature of 21. They 
were free to water and food. After the 8-week-old male C57BL/6J mice were fasted for 6 h, animals 
intraperitoneally injected 0.1 mg/g zafirlukast or vehicle and blood glucose and insulin levels were 
monitored. For glucose tolerance test, animals were fasted for overnight (16 h) and administrated 0.1 
mg/g zafirlukast plus 2 mg/g D-glucose. Blood glucose level were assessed at indicated times. The 
blood glucose levels were determined by tail blood on glucometer and serum insulin level were 
estimated by ELISA (Shibayagi). 
 
Insulin secretion assay 
 
MIN6 cells were plated in 96-well plates (4 × 105 cells/well) and cultured for 3 days. Before 
experiment, cells were washed in phosphate-buffered saline (PBS) and equilibrated with 2.8 mM 
glucose in Kreb’s buffer (KRB; 137 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 
mM CaCl2, 25 mM NaHCO3, and 10 mM HEPES, adjusted to pH 7.4 with NaOH before the addition 
of 3 g/L bovine serum albumin [BSA]) for 1 h. Size-matched medium islets were equilibrated in KRB 
with 2.8 mM glucose for 1 h and transferred to a 48-well plate (20 islets/well). MIN6 cells and 
pancreatic islets were stimulated with zafirlukast (Z4152; Sigma), pranlukast (Sigma), or montelukast 
(Sigma) in 300 μL of KRB plus 1 mM glucose and 20 mM glucose for 1 h. The supernatant was 
collected and the amount of insulin was quantified with an insulin enzyme-linked immunosorbent assay 
(ELISA) kit (Shibayagi). All steps were performed in a CO2 cell incubator. 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay 
 
Following chemical stimulation for 24 h, MIN6 cells were supplemented with MTT and 
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incubated for 4 h. The cells were then incubated with dimethyl sulfoxide to dissolve the formazan by 
shaking for 5 min and the absorbance was measured. 
 
Total insulin content 
 
Following treatment with zafirlukast, pranlukast and montelukast, MIN6 cells were washed in 
PBS and lysed in radioimmunoprecipitation assay (RIPA) buffer (#89900; Thermo Fisher Scientific). 
The total insulin content of the lysed extracts was measured by ELISA. 
 
Determination of intracellular Ca2+ 
 
After MIN6 cells were grown on glass coverslips coated with poly-L-lysine for 2 days, the cells 
were washed twice and loaded with fura-2-acetoxymethyl ester (Fura-2AM; final concentration 2 μM) 
in KRB for 1 h. The coverslips were then washed three times and inserted into a microscope holder in 
contact with 500 μL of buffer at 37°C. The chemicals (50 μM zafirlukast, montelukast, or pranlukast; 1 
μM nifedipine; 1 μM thapsigargin) were applied on top of the imaged cells, as indicated in the figure 
legends. The excitation signals were measured using a fluorimeter to monitor Fura-2AM fluorescence 




The pancreas of 8-week-old male C57BL/6J mice was inflated with 3 mL of 1 mg/mL collagenase 
(Roche) in Hank’s buffered saline solution (HBSS; Welgene), which was modified with 25 mM HEPES 
and adjusted to pH 7.4 with NaOH, and 0.25% (w/v) BSA was added. The collagenase-injected pancreas 
was incubated in a 37°C water bath for 15 min and manually shaken every 5 min. The digested pancreas 
was washed with modified HBSS on ice three times. Islets were separated by density gradient in Bicoll 
solution (Biochrom) and handpicked under a dissection microscope. Islets were cultured in RPMI-1640 




MIN6 cells treated with leukotriene receptor antagonists were lysed in RIPA buffer (Thermo 
Fisher Scientific), which included a cocktail of protease and phosphatase inhibitors according to the 
manufacturer’s instructions. Total protein concentration was estimated with the Pierce BCA Protein 
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Assay Kit (Thermo Fisher Scientific). Total protein was separated by gel electrophoresis and transferred 
to polyvinylidene fluoride membranes (Millipore). The membrane was blocked with 5% (w/v) fat-free 
milk and incubated with primary antibodies overnight at 4°C. After washing with Tris Buffered Saline 
with Tween 20 buffer, the membrane was incubated with horseradish peroxidase-labeled secondary 
antibody and proteins were visualized with enhanced chemiluminescence reagents (GE Healthcare Life 
Sciences). Anti-phospho-CaMKII (#3361), anti-phospho-AKT (#9271), and anti-phospho-ERK (#9101) 
antibodies were obtained from Cell Signaling. Anti-CaMKII (sc-5306), anti-AKT (sc-1619), and anti-
ERK (sc-154) antibodies were obtained from Santa Cruz Biotechnology and the anti-β-actin 




Zafirlukast increased insulin secretion in both low and high glucose conditions 
 
To investigate the physiological role of zafirlukast on the function of pancreatic β-cells, MIN6 
cells were treated with zafirlukast for 1 h and the level of secreted insulin was measured in low (2.8 
mM) and high (16.7 mM) glucose conditions. Interestingly, we found that zafirlukast markedly 
increased insulin secretion in the basal condition (2.8 mM glucose; approximately 4.4-fold increase 
compared with the control) and glucose-induced insulin secretion (16.7 mM glucose, approximately 1.7 
fold-increase compared with the control) at approximately 50 μM zafirlukast which is the maximum 
effect concentration (Emax). In the dose-response curve, the half maximal effective concentration (EC50) 
was 29.8 ± 1.6 and 22.7 ± 2.3 μM in the basal and high glucose conditions, respectively (Figure 3.1A, 
B). Next, we performed an MTT assay to evaluate the cytotoxicity of zafirlukast in the MIN6 cell line. 
The absorbances at concentrations up to nearly 80 μM were comparable between the control and 
zafirlukast-treated groups and cell viability was not altered following exposure to zafirlukast at Emax, 
indicating zafirlukast potentiates insulin secretion without inducing cell cytotoxicity (Figure 3.1C). 
Thus, zafirlukast induces regulated exocytosis of insulin vesicles, resulting in increased insulin 
secretion in pancreatic β-cells. 
 
Only zafirlukast among CysLTR1 antagonists induced insulin secretion 
 
To determine whether the effect of zafirlukast on pancreatic β-cells was related to its intrinsic 
function as a CysLTR1 antagonist, we performed the insulin secretion assay with other antagonists, 
namely montelukast and pranlukast, which also act on CysLTR1. The chemical structures of these 
63 
 
antagonists are distinct (Figure 3.2A), although they have similar receptor-binding affinities for 
CysLTR1 [12]. Zafirlukast increased insulin secretion in a dose-dependent manner in low (2.8 mM) and 
high (16.7 mM) glucose conditions. However, the level of secreted insulin did not change following 
treatment with pranlukast, and montelukast markedly inhibited glucose-stimulated insulin secretion 
(GSIS) (Figure 3.2B). To estimate the difference in the internal total insulin contents causes alteration 
in insulin secretory responses, we measured total insulin content following treatment with montelukast, 
pranlukast, and zafirlukast. Following stimulation with each of the CysLTR1 antagonists, total insulin 
content was unaffected in both the low and high glucose conditions (Figure 3.2C). Furthermore, 
absorbance values were similar between the control and the CysLTR1 antagonist-treated groups at the 
indicated concentrations, suggesting cell viability was not affected by CysLTR1 antagonist treatment at 
the different concentrations (Figure 3.2D). Thus, among the CysLTR1 antagonists, only zafirlukast 
promoted insulin secretion and acted on pancreatic β-cells by triggering activation of the insulin 
secretory pathway rather than exerting its intrinsic function as a CysLTR1 antagonist. 
 
Zafirlukast, but not montelukast or pranlukast, increased [Ca2+]i in MIN6 cells 
 
The elevation in [Ca2+]i level is critical for insulin exocytosis, which subsequently induces insulin 
secretion [13]. Zafirlukast induced a greater increase in insulin secretion in low (2.8 mM) compared 
with high (16.7 mM) glucose conditions, suggesting that zafirlukast is directly involved in the regulation 
of insulin secretion in the absence of glucose stimulation. Next, to assess whether zafirlukast can alter 
responsiveness, we performed calcium imaging with the fluorescent calcium indicator Fura-2AM. In 
this study, zafirlukast was tested under low glucose conditions, which eliminates the stimulating effects 
of glucose on insulin secretion. We analyzed transient calcium response triggered by treatment with 
zafirlukast, pranlukast, and montelukast during Fura-2AM loading. A significant increase in the Ca2+ 
response was observed following treatment with zafirlukast at the Emax of 50 μM, resulting in an increase 
in the ratio of 340 nm to 380 nm fluorescence. However, no change in the Ca2+ response following 
treatment with montelukast and pranlukast was observed (Figure 3.3A–C). These results show that 
zafirlukast specifically evoked a rapid and high increase in [Ca2+]i, resulting in enhanced exocytosis of 
insulin vesicles in pancreatic β-cells. 
 
Zafirlukast elevates [Ca2+]i levels and increases insulin secretion in isolated primary islets 
 
Next, to confirm the effect of zafirlukast on insulin secretion ex vivo, we performed an insulin 
secretion assay using primary islets isolated from 8-week-old C57BL/6 mice. In isolated pancreatic 
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islets, zafirlukast substantially increased insulin release in a dose-dependent manner from 9.6 ± 0.9 to 
25.5 ± 1.2 ng·mL–1 in the 2.8 mM glucose condition and from 16.5 ± 1.4 to 25.8 ± 0.8 ng·mL–1 in the 
16.7 mM glucose condition (Figure 3.4A). To estimate the influence of zafirlukast on [Ca2+]i in 
pancreatic islets, we recorded the calcium response in primary pancreatic islets followed by treatment 
with zafirlukast at the Emax of 50 μM. The addition of zafirlukast increased the 340 nm to 380 nm ratio 
within a few seconds, indicating zafirlukast significantly amplified [Ca2+]i levels. The increase in [Ca2+]i 
triggered by zafirlukast increased initially and then plateaued (Figure 3.4B,C). In conclusion, zafirlukast 
significantly potentiates insulin secretion in pancreatic β-cells by increasing [Ca2+]i levels. 
 
Zafirlukast-dependent increase in [Ca2+]i induces activation of key molecular events 
 
The stimulation of pancreatic β-cells by zafirlukast induces an increase in [Ca2+]i. The increase 
in [Ca2+]i propagates primary signals through the CaMKII, AKT, and ERK signaling pathways, which 
positively regulate insulin secretion [14-16]. To characterize the activation and regulation of key 
proteins by zafirlukast, we examined the phosphorylation of CaMKII, AKT, and ERK in a dose- and 
time-dependent manner in MIN6 cells following zafirlukast treatment. Lysates at the indicated 
concentrations and times were subjected to western blot analysis to assess phosphorylation. 
Interestingly, the phosphorylation of CaMKII, AKT, and ERK was significantly increased in a dose-
dependent manner and its phosphorylation increased at approximately 15 min and was sustained until 
1 h (Figure 3.5A, B). Interestingly, treatment with pranlukast slightly induced the ERK pathway, but 
not the CaMKII and AKT pathways, resulting in no change in insulin secretion. However, treatment 
with montelukast markedly suppressed the expression of phosphorylated AKT (p-AKT) and p-ERK 
(Figure 3.8). These results are consistent with the results of the insulin secretion assay, indicating that 
zafirlukast stimulates insulin secretion, while pranlukast does not alter insulin secretion, and 
montelukast inhibits GSIS. Taken together, our results indicate that zafirlukast induces phosphorylation 
of key signaling proteins in pancreatic β-cells. 
 
Zafirlukast induced extracellular calcium influx through L-type Ca2+ channels 
 
We next determined whether the increase in [Ca2+]i was derived from an extracellular or 
intracellular source of Ca2+. In the absence of extracellular Ca2+ (Ca2+-free KRB medium), the 
zafirlukast-stimulated [Ca2+]i levels were reduced compared with those observed in Ca2+-containing 
KRB, although the [Ca2+]i level was considerably increased via intracellular Ca2+ mobilization by 
thapsigargin (Figure 3.9). Thus, the results strongly suggest that the effect of zafirlukast on insulin 
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secretion is primarily due to the entry of extracellular Ca2+ rather than intracellular Ca2+ from the 
endoplasmic reticulum. Ca2+ influx through L-VDCCs is critical for insulin secretion [17]. Thus, we 
analyzed the involvement of these channels in zafirlukast-dependent effects using nifedipine, a DHP L-
VDCC antagonist, which suppresses GSIS, but has no effect on the basal levels of Ca2+. Fluorescent 
calcium imaging showed that application of nifedipine significantly inhibited the zafirlukast-dependent 
increase in [Ca2+]i (Figure 3.6A). Consistent with this, nifedipine potently reduced zafirlukast-
dependent insulin secretion in both low (2.8 mM) and high (16.7 mM) glucose conditions (Figure 3.6B). 
Moreover, zafirlukast stimulated the phosphorylation of CaMKII, AKT, and ERK in pancreatic β-cells, 
but this effect was prevented in the presence of nifedipine (Figure 3.6C). These findings suggest that 
zafirlukast induces Ca2+ influx through L-VDCCs, leading to enhanced insulin secretion in pancreatic 
β-cells. 
 
Zafirlukast lowers blood glucose levels by increasing insulin secretion in vivo 
 
To assess whether zafirlukast induced hypoglycemic effects in mice, 8-week-old C57BL/6J mice 
were administered 0.1 mg/g zafirlukast via intraperitoneal injection and blood glucose levels were 
monitored. Upon injection of zafirlukast, blood glucose levels dropped in the normal glycemic mice 
(33.5 ± 0.6% reduction, P = 0.01 compared with vehicle; Figure 3.7A). The glucose-lowering effect of 
zafirlukast was accompanied by an increase in the level of plasma insulin at 90 min (0.07 ± 0.01 and 
0.14 ± 0.02 ng·mL–1 for vehicle and zafirlukast, respectively) and 120 min (0.06 ± 0.003 and 0.16 ± 
0.02 ng·mL–1 for vehicle and zafirlukast, respectively), suggesting that the effects of zafirlukast were a 
result of the increased insulin secretion from pancreatic β-cells (Figure 3.7B). We next measured blood 
glucose levels in C57BL/6J mice following glucose administration to rigorously assess the glucose-
lowering effect of zafirlukast (0.1 mg/g) in vivo. The glucose-lowering effect of zafirlukast was also 
observed in mice at 90 and 120 min during an intraperitoneal glucose tolerance test (29.3 ± 7.9% 
reduction, P = 0.01 for 90 min and 46.7 ± 6.6% reduction, P = 0.001 for 120 min; Figure 3.7C). These 
results show that zafirlukast functions as an insulin secretagogue and exhibits glucose-lowering effects 
in vivo. 
 
3.4. Conclusion and Discussion 
 
It has long been known that zafirlukast have important role in the inflammatory processes of 
asthma [1]. However, its function and underlying mechanism in pancreatic β-cells remains to be 
elucidated. In this study, we examined the effects of zafirlukast on hypoglycemia in terms of insulin 
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secretion in pancreatic β-cells. We demonstrated that zafirlukast potentiates insulin secretion in MIN6 
cells and primary pancreatic islets in both basal (2.8 mM) and high glucose (16.7 mM) conditions. The 
increase in insulin secretion is primarily elicited by extracellular Ca2+ influx through L-VDCCs, 
resulting in increased phosphorylation of CaMKII, AKT, and ERK. Taken together, these findings 
suggest that zafirlukast can increase [Ca2+]i levels and activate key signaling molecules, resulting in 
increased insulin secretion. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to alleviate chronic inflammation by 
blocking the cyclooxygenase pathway by inhibiting cyclooxygenase, which contributes to the formation 
of pro-inflammatory mediators such as prostaglandins and thromboxane [18, 19]. It has been reported 
that at high doses NSAIDs such as salicylates lower blood glucose levels [20, 21] and ibuprofen use in 
diabetic patients has been shown to induce hypoglycemia [22]. Furthermore, meclofenamic acid 
stimulates insulin secretion from pancreatic β-cells by inhibiting KATP channels, which is followed by 
an increase in [Ca2+]i. Flufenamic acid and acetylsalicylic acid have also been shown to depolarize INS-
1 cells by inhibiting KATP channels [23]. In addition, zafirlukast provides effective relief of inflammation 
by inhibiting the 5-lipoxygenase pathway by blocking CysLTR1 [2, 24]. We wondered whether the 
zafirlukast-dependent increase in insulin secretion was related to its intrinsic anti-inflammatory function. 
We examined the effects on insulin release of pranlukast and montelukast, which, like zafirlukast, 
function as CysLTR1 antagonists, but with different chemical structures (Figure 3.2A). Interestingly, 
potentiation of insulin secretion was zafirlukast-dependent, and not pranlukast- or montelukast-
dependent (Figure 3.2B). Montelukast suppressed monocyte chemotactic protein 1 (MCP-1)-dependent 
[Ca2+]i increase and phospho-p38 mitogen-activate protein kinase expression in THP-1 cells, abolishing 
monocyte chemotaxis induced by MCP-1 [25]. Our results show that montelukast inhibited GSIS from 
pancreatic β-cells, which could be caused by inhibition of glucose-stimulated [Ca2+]i. Furthermore, 
CysLTR1, which zafirlukast binds to as an antagonist, is rarely expressed in pancreatic β-cells [26], 
suggesting that zafirlukast-induced insulin release was not associated with its intrinsic function as a 
CysLTR1 antagonist. Altogether, these results suggest that there might be potential off-target effects of 
zafirlukast in pancreatic β-cells. 
Various signaling pathways might maintain or increase insulin secretion [27]. In pancreatic β-
cells, the rise in [Ca2+]i results in activation of CaMKII, which mediates ERK phosphorylation to exert 
an insulin secretory response [14, 28, 29]. This induces cytoskeletal rearrangement [30, 31] and 
phosphorylation of components of the secretory machinery, such as synapsin I [32], microtubule-
associated protein 2 [33], and vesicle-associated membrane protein (VAMP)/synaptobrevin [34]. 
Furthermore, AKT pathways optimize β-cell function, including cell survival [16] and insulin secretion 
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by inducing activation of SNARE proteins such as STX1, SNAP25, and VAMP2 [15, 35] and 
modulation of L-VDCCs [36]. Interestingly, zafirlukast was able to stimulate insulin secretion by 
inducing Ca2+ entry and phosphorylation of CaMKII, AKT, and ERK. These results were not observed 
in MIN6 cells treated with pranlukast and montelukast. Rather, the AKT and ERK pathways were 
substantially inhibited following treatment with montelukast, which suppressed GSIS (Figure 3.8). 
Our results showed that zafirlukast failed to induce an increase in [Ca2+]i in the absence of 
extracellular Ca2+ sources, indicating that zafirlukast primarily promoted the increase in [Ca2+]i via 
extracellular Ca2+ rather than intracellular Ca2+. In pancreatic β-cells, Ca2+ influx via L-VDCCs is 
essential for insulin secretion [17]. Indeed, treatment with nifedipine, a DHP L-VDCC antagonist, 
reduced the effect of zafirlukast on both [Ca2+]i and insulin secretion. Furthermore, nifedipine exposure 
eliminated the zafirlukast-dependent phosphorylation of CaMKII, AKT, and ERK. We observed a small 
nifedipine-resistant portion of the zafirlukast-induced elevation in [Ca2+]i and insulin secretion, 
suggesting either incomplete blockage of L-VDCCs or that another type of Ca2+ channel, such as N- or 
P/Q-type Ca2+ channels [37], might be targeted by zafirlukast. However, the blockade of L-VDCCs via 
a specific DHP-sensitive inhibitor significantly inhibited the zafirlukast-dependent effects on pancreatic 
β-cells, indicating that increased insulin secretion by zafirlukast was primarily mediated via L-VDCCs. 
Zafirlukast also effectively regulated insulin secretion and glucose levels in vivo, evidenced by the 
increased insulin levels and decreased blood glucose following injection of zafirlukast in mice. 
Zafirlukast has been prescribed for asthma patients to be taken on an empty stomach [7], which 
represents a physiological in vivo state similar to low (2.8 mM) glucose levels in vitro. Our evidence 
showed that zafirlukast has a greater effect on insulin secretion in low levels of glucose. Therefore, 
taking zafirlukast on an empty stomach can cause severe adverse effects such as hypoglycemia and our 
results suggestion that greater attention may be necessary when prescribing zafirlukast, especially in 
low glucose conditions. On the other hand, zafirlukast also affects insulin secretion in high glucose 
(16.7 mM) conditions, indicating the possible use of zafirlukast in the control of blood glucose levels. 
The potential use of zafirlukast in the treatment of type 2 diabetes deserves further investigation. 
Overall, we have identified a novel function of zafirlukast as a regulator of insulin secretion in 
pancreatic β-cells. We have shown that zafirlukast can stimulate insulin secretion by promoting Ca2+ 
entry via L-VDCCs, resulting in increased phosphorylation of CaMKII, AKT, and ERK. In addition to 





Figure 3.1. Zafirlukast-dependent potentiation of insulin secretion in MIN6 cells. 
(A) Dose-response curve showing the effect of zafirlukast on insulin secretion in low (2.8 mM) and 
(B) high (16.7 mM) glucose conditions (n = 4). (C) Dose-response curve showing the effect of 




Figure 3.2. Distinct effect of zafirlukast on insulin secretion among cysteinyl leukotriene 
receptor 1 (CysLTR1) antagonists. 
(A) Chemical structures of the CysLTR1 antagonists montelukast, pranlukast, and zafirlukast. (B) 
Level of secreted insulin following treatment with CysLTR1 antagonists in MIN6 cells in low (2.8 
mM) and high (16.7 mM) glucose conditions (n = 4). (C) Total insulin content and (D) cell viability 
determined with the MTT assay following exposure to CysLTR1 antagonists (n = 3). Error bars 
represent SEM. **P < 0.01 and ***P < 0.001, compared with the control in low glucose 
(zafirlukast). ##P < 0.01 and ###P < 0.001, compared with the control in high glucose (zafirlukast). 




Figure 3.3. Zafirlukast-induced increase in intracellular calcium ([Ca2+]i) in MIN6 cells.  
(A) Pseudocolored images showing the relative concentration of calcium visualized by the fura-2-
acetoxymethyl ester (Fura-2AM) fluorescence ratio (F340/F380 nm) following stimulation with 
each CysLTR1 antagonist in MIN6 cells. Blue and red correspond to low and high [Ca2+]i, 
respectively. (B) Change in the F340/F380 nm ratio at different time points and (C) basal and peak 
F340/F380 nm ratio following treatment with each CysLTR1 antagonist (n = 7–12 per group). Scale 




Figure 3.4. Increase in insulin secretion and [Ca2+]i following stimulation with zafirlukast in 
primary pancreatic islets. 
(A) Secreted insulin level following stimulation with zafirlukast in low and high glucose conditions 
in primary pancreatic islets. (B) Pseudocolored image of the F340/F380 nm ratio following 
zafirlukast treatment in cultured primary islets (C) Change in the F340/F380 nm ratio at different 
time points and (C) basal and peak F340/F380 nm ratio following exposure to zafirlukast (n = 10 




Figure 3.5. Zafirlukast-induced phosphorylation of CaMKII, AKT, and ERK. 
(A) Western blot analysis showing phosphorylation of CaMKII, AKT, and ERK proteins following 
treatment of MIN6 cells with 50 μM zafirlukast for 1 h in a dose-dependent and (B) time-dependent 
manner. MIN6 cells were incubated with zafirlukast at the indicated concentrations for 1 h and 
protein lysates were used for western blot analysis. To assess time-dependent changes, proteins 





Figure 3.6. Effect of zafirlukast on insulin secretion elicited by extracellular Ca2+ influx 
through L-type voltage dependent calcium channels (L-VDCCs). 
(A) Change in the F340/F380 nm ratio (left panel) and maximum change in the F340/F380 nm 
response (right panel) following zafirlukast treatment in the absence or presence of nifedipine. 
MIN6 cells were incubated with nifedipine before the addition of zafirlukast and the change in the 
F340/F380 nm ratio was monitored following treatment with zafirlukast (n = 8 per group). (B) 
Secreted insulin level (n = 3) and (C) western blot analysis in MIN6 cells in the presence of basal 
or high glucose with or without 1 μM nifedipine as indicated. Error bars represent SEM. ***P < 
0.001, compared with the control in low glucose. ###P < 0.001, compared with the control in high 
glucose. $$$P < 0.001, compared with the control in low glucose with zafirlukast. +++P < 0.001, 

































Figure 3.7. Glucose-lowering effect of zafirlukast as a result of increased insulin secretion in 
vivo. 
(A) Blood glucose and (B) serum insulin levels in 8-week-old C57BL/6J mice treated with vehicle 
or 0.1 mg/g zafirlukast (n = 3 per group). (C) Blood glucose levels during an intraperitoneal glucose 
tolerance test in 8-week-old C57BL/6J mice dosed with vehicle or 0.1 mg/g zafirlukast (n = 5 per 





Figure 3.8. Pranlukast- and montelukast-induced phosphorylation of CaMKII, AKT, and 
ERK. 
(A) Western blot analysis showing phosphorylation of CaMKII, AKT, and ERK in a dose-
dependent manner following treatment with pranlukast and (B) montelukast for 1 h in MIN6 cells. 
MIN6 cells were incubated in basal and high glucose medium with pranlukast and montelukast at 





























Figure 3.9. Effect of zafirlukast on [Ca2+]i in Ca2+-free Kreb’s buffer (KRB) medium. 
(A) Changes in the F340/F80 nm ratio at different time points in Ca2+-free KRB medium (n = 6). 
The Fura-2AM-loaded MIN6 cells were incubated in Ca2+-free KRB and stimulated with 50 μM 
zafirlukast and 1 μM thapsigargin at the indicated times. 
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유니스트에서 공부를 시작한지 어느덧 9년이라는 시간이 흘렀습니다. 박사 과정을 무
사히 마무리하기까지 많은 분들의 도움이 있었습니다. 이 글을 통해 감사의 인사를 드리
고자 합니다. 
제일 먼저, 항상 저의 연구에 여러 가지 가능성과 많은 경험의 기회를 주신 서판길 교
수님 감사합니다. 교수님께서 몸소 가르쳐 주신 사람 인연의 소중함, 연구 윤리와 연구자
의 도덕적 면모 또한 명심하겠습니다. 바쁘신 와중에도 진심 어린 조언 해주시고 논문을 
끝까지 마무리할 수 있도록 많은 도움 주신 최장현 교수님, 채영찬 교수님 감사합니다. 
학부 연구 참여 기간 동안 많은 실험 기술을 가르쳐 주신 박찬영 교수님께도 감사의 인
사를 드립니다. 
박사 학위 논문을 마무리하면서 되돌아보면 힘든 일도, 포기하고 싶었던 적도 많았습
니다. 그때마다 실험실 선배와 동료분들로부터 많은 힘을 받았습니다. 지도 교수님만큼 
의지했던 저의 사수 현준선배와 엄마처럼 든든했던 유진선배 감사합니다. 어려울 때마다 
불러 조언해주시고 도움 주신 용렬선배 감사합니다. 항상 긍정적인 힘을 주신 서영교 박
사님, 강두석 박사님, 이철 박사님, 박광일 박사님, 김광연 박사님, 한 공간에서 함께 연
구할 수 있어 영광이었습니다. 항상 옳은 생각이 무엇인지 알려주었던 경진선배, 도움 청
할 때마다 흔쾌히 손을 내주었던 밝은 혜윤이도 정말 고맙습니다. 행정적으로 실험적으
로 지원해주신 김영미 선생님, 이경은 선생님, 김도희 선생님, 정우도 감사합니다. 다른 
곳에서 꿈을 펼치고 있는 균희, 서림, 샛별, 슬기, 제표오빠, 원명이 때문에도 정말 기뻤
습니다. 흔쾌히 췌장 세포 분리를 알려주신 김가영 박사님과 조언을 해주신 김재윤 박사
님께도 감사드립니다. 이제 막 입학하여 많은 시행착오를 겪고 있는 예지, 희원, 누리, 도
홍이도 고맙고 훌륭한 성과 내기를 바랍니다. 
누구보다 제가 박사학위를 무사히 마무리할 수 있기를 바랬을 저의 부모님, 아빠 엄마 
정말 감사합니다. 언제나 진심으로 응원해준 언니들 형부들께도 감사의 인사를 전합니다. 
항상 저에게 기쁨과 웃음을 주는 우리 조카 예준, 지호, 준우, 윤호도 고마워. 저의 박사 
학위를 진심으로 기뻐해주신 오빠 어머니 아버지께도 감사드립니다. 가족들의 아낌없는 
격려와 사랑 덕분에 학위를 잘 마칠 수 있었습니다.  
마지막으로, 한결 같은 사랑으로 저를 챙겨주었던 동선 오빠에게 박사 학위 취득의 영
광을 돌리고 싶습니다. 진심으로 고맙고, 저도 평생 사랑합니다. 
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